<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
<journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLoS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30934003</article-id>
<article-id pub-id-type="pmc">6443178</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0213770</article-id>
<article-id pub-id-type="publisher-id">PONE-D-18-19781</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and Health Sciences</subject>
<subj-group>
<subject>Nephrology</subject>
<subj-group>
<subject>Renal Cancer</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Genomics</subject>
<subj-group>
<subject>Human Genomics</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Organisms</subject>
<subj-group>
<subject>Viruses</subject>
<subj-group>
<subject>RNA viruses</subject>
<subj-group>
<subject>Retroviruses</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Microbiology</subject>
<subj-group>
<subject>Medical Microbiology</subject>
<subj-group>
<subject>Microbial Pathogens</subject>
<subj-group>
<subject>Viral Pathogens</subject>
<subj-group>
<subject>Retroviruses</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and Health Sciences</subject>
<subj-group>
<subject>Pathology and Laboratory Medicine</subject>
<subj-group>
<subject>Pathogens</subject>
<subj-group>
<subject>Microbial Pathogens</subject>
<subj-group>
<subject>Viral Pathogens</subject>
<subj-group>
<subject>Retroviruses</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Organisms</subject>
<subj-group>
<subject>Viruses</subject>
<subj-group>
<subject>Viral Pathogens</subject>
<subj-group>
<subject>Retroviruses</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Cell biology</subject>
<subj-group>
<subject>Chromosome biology</subject>
<subj-group>
<subject>Chromatin</subject>
<subj-group>
<subject>Chromatin modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Epigenetics</subject>
<subj-group>
<subject>Chromatin</subject>
<subj-group>
<subject>Chromatin modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Gene expression</subject>
<subj-group>
<subject>Chromatin</subject>
<subj-group>
<subject>Chromatin modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>DNA</subject>
<subj-group>
<subject>DNA modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Nucleic acids</subject>
<subj-group>
<subject>DNA</subject>
<subj-group>
<subject>DNA modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Epigenetics</subject>
<subj-group>
<subject>DNA modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Gene expression</subject>
<subj-group>
<subject>DNA modification</subject>
<subj-group>
<subject>DNA methylation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and Health Sciences</subject>
<subj-group>
<subject>Oncology</subject>
<subj-group>
<subject>Cancers and Neoplasms</subject>
<subj-group>
<subject>Lung and Intrathoracic Tumors</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Nucleic acids</subject>
<subj-group>
<subject>RNA</subject>
<subj-group>
<subject>Non-coding RNA</subject>
<subj-group>
<subject>Long non-coding RNAs</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Mutation</subject>
<subj-group>
<subject>Somatic Mutation</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Gene Expression</subject>
</subj-group>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Investigation of somatic single nucleotide variations in human endogenous retrovirus elements and their potential association with cancer</article-title>
<alt-title alt-title-type="running-head">SNVs in human endogenous retrovirus and their association with cancer</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Chang</surname>
<given-names>Ting-Chia</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Goud</surname>
<given-names>Santosh</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Torcivia-Rodriguez</surname>
<given-names>John</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Yu</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pan</surname>
<given-names>Qing</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kahsay</surname>
<given-names>Robel</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blomberg</surname>
<given-names>Jonas</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8823-9945</contrib-id>
<name>
<surname>Mazumder</surname>
<given-names>Raja</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label>
<addr-line>Department of Biochemistry &amp; Molecular Medicine, George Washington University Medical Center, Washington, DC, United States of America</addr-line></aff>
<aff id="aff002"><label>2</label>
<addr-line>The School of Systems Biology, George Mason University, Manassas, VA, United States of America</addr-line></aff>
<aff id="aff003"><label>3</label>
<addr-line>Department of Statistics, The George Washington University, Washington, DC, United States of America</addr-line></aff>
<aff id="aff004"><label>4</label>
<addr-line>Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden</addr-line></aff>
<aff id="aff005"><label>5</label>
<addr-line>McCormick Genomic and Proteomic Center, George Washington University, Washington, DC, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>Belshaw</surname>
<given-names>Robert</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"></xref>
</contrib>
</contrib-group>
<aff id="edit1">
<addr-line>Plymouth University, UNITED KINGDOM</addr-line>
</aff>
<author-notes>
<fn fn-type="COI-statement" id="coi001">
<p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email>mazumder@gwu.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>1</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>14</volume>
<issue>4</issue>
<elocation-id>e0213770</elocation-id>
<history>
<date date-type="received">
<day>3</day>
<month>7</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>2</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 Chang et al</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Chang et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="pone.0213770.pdf"></self-uri>
<abstract>
<p>Human endogenous retroviruses (HERVs) have been investigated for potential links with human cancer. However, the distribution of somatic nucleotide variations in HERV elements has not been explored in detail. This study aims to identify HERV elements with an over-representation of somatic mutations (hot spots) in cancer patients. Four HERV elements with mutation hotspots were identified that overlap with exons of four human protein coding genes. These hotspots were identified based on the significant over-representation (p&lt;8.62e-4) of non-synonymous single-nucleotide variations (nsSNVs). These genes are TNN (HERV-9/LTR12), OR4K15 (HERV-IP10F/LTR10F), ZNF99 (HERV-W/HERV17/LTR17), and KIR2DL1 (MST/MaLR). In an effort to identify mutations that effect survival, all nsSNVs were further evaluated and it was found that kidney cancer patients with mutation C2270G in ZNF99 have a significantly lower survival rate (hazard ratio = 2.6) compared to those without it. Among HERV elements in the human non-protein coding regions, we found 788 HERVs with significantly elevated numbers of somatic single-nucleotide variations (SNVs) (p&lt;1.60e-5). From this category the top three HERV elements with significantly over-represented SNVs are HERV-H/LTR7, HERV-9/LTR12 and HERV-L/MLT2. Majority of the SNVs in these 788 HERV elements are located in three DNA functional groups: long non-coding RNAs (lncRNAs) (60%), introns (22.2%) and transcriptional factor binding sites (TFBS) (14.8%). This study provides a list of mutational hotspots in HERVs, which could potentially be used as biomarkers and therapeutic targets.</p>
</abstract>
<funding-group>
<funding-statement>This work was supported by McCormick Genomic and Proteomic Center at George Washington University. There was no additional external funding received for this study.</funding-statement>
</funding-group>
<counts>
<fig-count count="7"></fig-count>
<table-count count="3"></table-count>
<page-count count="23"></page-count>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<title>Data Availability</title>
<p>All relevant data are within the paper and its Supporting Information files.</p>
</notes>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Background</title>
<p>Endogenous retroviruses (ERVs) have been embedded in the primate genomes for over 30 million years [<xref ref-type="bibr" rid="pone.0213770.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0213770.ref002">2</xref>]. Typically, the genetic structure of ERVs contains the internal coding sequencing of the four proviral genes (gag, pro, pol and env) along with two long terminal repeats (LTRs) [<xref ref-type="bibr" rid="pone.0213770.ref003">3</xref>]. Over the course of time, most ERVs in the human genome have been severely damaged in their original genetic structure due to the accumulation of mutations, insertions, deletions and translocations that have spliced out the original coding region of proviral genes between two flanking LTRs [<xref ref-type="bibr" rid="pone.0213770.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0213770.ref005">5</xref>]. Solitary LTRs are the most common ERVs within the human genome [<xref ref-type="bibr" rid="pone.0213770.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0213770.ref005">5</xref>].</p>
<p>Human endogenous retroviruses (HERVs) account for approximately eight percent of the human genome [<xref ref-type="bibr" rid="pone.0213770.ref006">6</xref>] and have been classified into three main classes I, II and III. This classification is based on sequence similarity to different genera of infectious retroviruses [<xref ref-type="bibr" rid="pone.0213770.ref007">7</xref>]. Over 22 distinct HERV groups across three classes have been reported [<xref ref-type="bibr" rid="pone.0213770.ref008">8</xref>]. Gamma- and Epsilon-retrovirus like (GE; earlier called Class I) HERVs are linked to gamma-retroviruses like murine leukemia virus (MLV); It includes HERV-W (HERV17/LTR17/ERV-W), HERV-H (HERV-H/LTR7), and other subgroups. The Alpha and Beta-retrovirus like (AB; earlier called Class II) HERVs [<xref ref-type="bibr" rid="pone.0213770.ref009">9</xref>] are related to beta-retroviruses such as mouse mammary tumor virus and include several types of HERV-K (HML families) elements. Spumavirus like (S; earlier called Class III) HERVs are distantly related to spumaviruses and include HERV-L (HERV-L/MLT2) and HERV-S (HERV18/LTR18). Classifications of HERV elements are currently not entirely consistent due to varying approaches used to detect HERV sequences [<xref ref-type="bibr" rid="pone.0213770.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0213770.ref010">10</xref>]. This leads to a variable number of identified HERV groups based on the bioinformatic methodology and algorithm used and can cause inconsistencies in HERV classification [<xref ref-type="bibr" rid="pone.0213770.ref011">11</xref>, <xref ref-type="bibr" rid="pone.0213770.ref012">12</xref>]. Recent work performed by Vargiu et al. has been able to systematically identify and classify 3,173 HERVs in the human genome [<xref ref-type="bibr" rid="pone.0213770.ref013">13</xref>], thereby providing some consistency in HERV classification. Of the 3,137 HERVs, 1,214 canonical (homogeneous) and 1,923 non-canonical (heterogenous) HERVs were separately placed into 39 and 31 groups (clades) respectively. This work builds upon a huge volume of previous work on repetitive elements and evolutionary analysis of ERVs [<xref ref-type="bibr" rid="pone.0213770.ref014">14</xref>, <xref ref-type="bibr" rid="pone.0213770.ref015">15</xref>] [<xref ref-type="bibr" rid="pone.0213770.ref016">16</xref>–<xref ref-type="bibr" rid="pone.0213770.ref018">18</xref>].</p>
<p>Over the course of evolution, majority of HERVs within the human genome have gradually lost their original protein coding functions [<xref ref-type="bibr" rid="pone.0213770.ref019">19</xref>]. However, HERVs have been indirectly linked to the various diseases, including human preimplantation embryogenesis [<xref ref-type="bibr" rid="pone.0213770.ref020">20</xref>], multiple sclerosis[<xref ref-type="bibr" rid="pone.0213770.ref021">21</xref>], cancers [<xref ref-type="bibr" rid="pone.0213770.ref022">22</xref>–<xref ref-type="bibr" rid="pone.0213770.ref024">24</xref>] and neurological disorders [<xref ref-type="bibr" rid="pone.0213770.ref025">25</xref>]. In cancers, for example, Np9, which is encoded by HERV-K (HML groups) elements, has been proposed to be involved in oncogenomic mechanisms through the LNX/Numb/Notch pathway [<xref ref-type="bibr" rid="pone.0213770.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0213770.ref027">27</xref>]. HERV LTRs have been reported to participate in human tumorigenesis by regulating the expression of its adjacent genes [<xref ref-type="bibr" rid="pone.0213770.ref028">28</xref>, <xref ref-type="bibr" rid="pone.0213770.ref029">29</xref>]. For example, a mutation found in a HERV LTR leads to the activation of syncytin-1 encoded by HERV-W Env with high expression in bladder carcinoma [<xref ref-type="bibr" rid="pone.0213770.ref030">30</xref>]. It has been proposed that somatic mutations are associated with aberrant activation of stem cell-associated retroviruses (SCAR) and with stem cell-like phenotypes of cancer cells, clinical intractability of human malignancies, and increased likelihood of therapy failure and death from cancer [<xref ref-type="bibr" rid="pone.0213770.ref031">31</xref>].</p>
<p>Next-Generation Sequencing (NGS) has immensely aided the identification of genetic variations and their role in human diseases [<xref ref-type="bibr" rid="pone.0213770.ref032">32</xref>–<xref ref-type="bibr" rid="pone.0213770.ref034">34</xref>]. The availability of single nucleotide variation (SNV) databases and locus specific disease-related annotation databases has helped researchers map mutations to potential biomarkers [<xref ref-type="bibr" rid="pone.0213770.ref035">35</xref>]. In this study, we have analyzed such datasets to explore pan-cancer mutations in HERV elements. Although, it has been shown in several studies that such pan-cancer analysis can help identify patterns of driver mutations [<xref ref-type="bibr" rid="pone.0213770.ref036">36</xref>–<xref ref-type="bibr" rid="pone.0213770.ref038">38</xref>], to the best of our knowledge no such study has been performed on HERV elements.</p>
<p>This study explores correlations between HERV elements and cancers by identifying somatic mutation hotspots in the human genome, followed by a detailed review of functional annotations available for these genomic regions.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Material and methods</title>
<sec id="sec003">
<title>Data integration</title>
<sec id="sec004">
<title>SNV data</title>
<p>All SNV data was retrieved from BioMuta. BioMuta v3.0 [<xref ref-type="bibr" rid="pone.0213770.ref035">35</xref>, <xref ref-type="bibr" rid="pone.0213770.ref039">39</xref>] is a comprehensive non-redundant data set of SNVs found in cancer within the coding region of hg19/GRCh37 compiled from multiple sources, including The Cancer Genome Atlas (TCGA) [<xref ref-type="bibr" rid="pone.0213770.ref040">40</xref>], CGHub data portal (<ext-link ext-link-type="uri" xlink:href="https://cghub.ucsc.edu/">https://cghub.ucsc.edu/</ext-link>), ClinVar [<xref ref-type="bibr" rid="pone.0213770.ref041">41</xref>], Catalog Somatic Mutations in Cancer (COSMIC) [<xref ref-type="bibr" rid="pone.0213770.ref042">42</xref>], International Cancer Genome Consortium (ICGC) [<xref ref-type="bibr" rid="pone.0213770.ref043">43</xref>], Integrative Onco Genomics (IntOGen) [<xref ref-type="bibr" rid="pone.0213770.ref044">44</xref>], UniProtKB [<xref ref-type="bibr" rid="pone.0213770.ref045">45</xref>], literature mining, and manual curation. For this study, BioMuta v3.0 was expanded to include SNVs in the non-coding regions of the human genome (hg19/GRCh37). The non-coding SNVs mutation data was extracted from (ICGC) (Version 23) [<xref ref-type="bibr" rid="pone.0213770.ref043">43</xref>] and COSMIC (version 79) [<xref ref-type="bibr" rid="pone.0213770.ref042">42</xref>]. This non-coding database was derived from whole genome sequencing (WGS) data and was restricted to regions excluding coding domain sequences based on the annotations available through UCSC genome browser (<ext-link ext-link-type="uri" xlink:href="https://genome.ucsc.edu/">https://genome.ucsc.edu/</ext-link>). It is important to note that single nucleotide polymorphisms (SNPs) were filtered out for both coding and non-coding SNV datasets by Mutect 2 for TCGA [<xref ref-type="bibr" rid="pone.0213770.ref046">46</xref>] and by MuTect and Strelka [<xref ref-type="bibr" rid="pone.0213770.ref047">47</xref>] for ICGC [<xref ref-type="bibr" rid="pone.0213770.ref048">48</xref>] and DNA-Seq analysis pipelines for TCGA is listed in (<ext-link ext-link-type="uri" xlink:href="https://docs.gdc.cancer.gov/Data/Bioinformatics_Pipelines/">https://docs.gdc.cancer.gov/Data/Bioinformatics_Pipelines/</ext-link>).SNV identification in repetitive regions is handled based on published methods [<xref ref-type="bibr" rid="pone.0213770.ref049">49</xref>–<xref ref-type="bibr" rid="pone.0213770.ref051">51</xref>].</p>
</sec>
<sec id="sec005">
<title>HERV data</title>
<p>Comprehensive HERV data set based on hg19/GRCh37 (<xref ref-type="supplementary-material" rid="pone.0213770.s003">S1 Table</xref>) was obtained using methods described by Vargiu et al. [<xref ref-type="bibr" rid="pone.0213770.ref013">13</xref>]. The detection of HERV elements is based on three basic principles: (a) detection of candidate LTRs, (b) detection of chains of conserved retroviral motifs fulfilling distance constraints, and (c) an attempt at reconstruction of original retroviral protein sequences, combining alignment, codon statistics and properties of protein ends. All classifications and nomenclature of HERV elements that is used for this study is available in <xref ref-type="supplementary-material" rid="pone.0213770.s004">S2 Table</xref>. The term canonical HERV is defined to be a HERV sequence that comes from one HERV group [<xref ref-type="bibr" rid="pone.0213770.ref013">13</xref>]. Otherwise, a HERV element is considered non-canonical if composed of two or more HERV groups. The names of groups are based on prior usage in the literature and from RepeatMasker [<xref ref-type="bibr" rid="pone.0213770.ref016">16</xref>].</p>
</sec>
</sec>
<sec id="sec006">
<title>DNA functional elements data</title>
<p>The DNA functional elements data set for protein non-coding regions is comprised of: tRNA (version 1.23) [<xref ref-type="bibr" rid="pone.0213770.ref052">52</xref>–<xref ref-type="bibr" rid="pone.0213770.ref054">54</xref>]; CpG island (download date: Oct. 2015) (UCSC Genome Browser); Open Regulatory Annotations (version 3.0) [<xref ref-type="bibr" rid="pone.0213770.ref055">55</xref>, <xref ref-type="bibr" rid="pone.0213770.ref056">56</xref>]; microRNA sites and their target sites (version 7.1) [<xref ref-type="bibr" rid="pone.0213770.ref057">57</xref>]; pseudo exons (release 60) [<xref ref-type="bibr" rid="pone.0213770.ref058">58</xref>, <xref ref-type="bibr" rid="pone.0213770.ref059">59</xref>]; VISTA enhancers (download date: Oct. 2015) [<xref ref-type="bibr" rid="pone.0213770.ref060">60</xref>], HAca box elements; CDBox elements; SnoRNA/ScaRNA sites (version 3) [<xref ref-type="bibr" rid="pone.0213770.ref061">61</xref>], alternative splice sites (download date: Oct. 2015) (UCSC genome Browser); transcription factor binding sites (version 3.0) [<xref ref-type="bibr" rid="pone.0213770.ref062">62</xref>, <xref ref-type="bibr" rid="pone.0213770.ref063">63</xref>], introns (download date: Oct. 2015) (UCSC genome Browser), and long non-coding RNAs (v4.0) [<xref ref-type="bibr" rid="pone.0213770.ref064">64</xref>].</p>
</sec>
<sec id="sec007">
<title>Over-representation analysis</title>
<p>SNVs were mapped to HERV elements based on their genomic coordinates. SNVs could be either from human protein coding region or protein non-coding region. Retrovirus coding region such as gag, pro, pol and env are not considered as human protein coding region unless there is annotation in UniProtKB/Swiss-Prot [<xref ref-type="bibr" rid="pone.0213770.ref045">45</xref>] that indicates that they are indeed part of a protein coding sequence. The Binomial test [<xref ref-type="bibr" rid="pone.0213770.ref065">65</xref>, <xref ref-type="bibr" rid="pone.0213770.ref066">66</xref>] was then used to evaluate the significance of the over-represented SNVs in each HERV element, by comparing its observed SNV number to the expected SNV number in each HERV element on human protein coding region or non-coding region, respectively [<xref ref-type="bibr" rid="pone.0213770.ref067">67</xref>, <xref ref-type="bibr" rid="pone.0213770.ref068">68</xref>]. The calculation of the expected number n(E) of SNV sites in each HERV element is expressed as follows:
<disp-formula id="pone.0213770.e001"><alternatives><graphic id="pone.0213770.e001g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pone.0213770.e001.jpg"></graphic><mml:math id="M1"><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>n</mml:mi><mml:mo>(</mml:mo><mml:mi>F</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:mfrac></mml:math></alternatives></disp-formula></p>
<p>Where n(F) is the total number of nucleotides at each HERV element (total base pairs of each HERV element) and L is the total number of nucleotides of the genome (total base pairs of human chromosomal protein coding or non-coding region). The probability p(F) of observing a nucleotide from the human genome at a certain HERV element is calculated by taking the value of n(F) divided by total length of human chromosomal protein coding or protein non-coding genome L.</p>
<disp-formula id="pone.0213770.e002">
<alternatives>
<graphic id="pone.0213770.e002g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pone.0213770.e002.jpg"></graphic>
<mml:math id="M2">
<mml:mi>n</mml:mi>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mi>E</mml:mi>
</mml:mrow>
<mml:mo>)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>N</mml:mi>
<mml:mo>×</mml:mo>
<mml:mi>p</mml:mi>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mi>F</mml:mi>
</mml:mrow>
<mml:mo>)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>N</mml:mi>
<mml:mo>×</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mi>n</mml:mi>
<mml:mo>(</mml:mo>
<mml:mi>F</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
</mml:mfrac>
</mml:math>
</alternatives>
</disp-formula>
<p>Here, N is the total number of variation sites found in the human protein coding or non-coding part of the genome. Assuming that somatic SNV sites are equally likely to be found along the entire genome, the value of n(E) gives us the expected number of SNV sites that would be found in the HERV regions of the genome. The expected ratio in whole human genome is 0.019 (total number of SNVs in coding and non-coding region divided by total number of bases in the human genome). To evaluate the expected ratio in the whole genome, random sampling of permutation [<xref ref-type="bibr" rid="pone.0213770.ref069">69</xref>] was performed in R (<ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/">http://www.R-project.org/</ext-link>) for comparing the observed ratio in random fragments and calculating the number of SNVs in each fragment (1000 bases in one fragment). (<xref ref-type="supplementary-material" rid="pone.0213770.s005">S3 Table</xref>)</p>
<p>Binomial statistic was used to calculate the p-value of the expected versus observed as follows:
<disp-formula id="pone.0213770.e003"><alternatives><graphic id="pone.0213770.e003g" mimetype="image" orientation="portrait" position="anchor" xlink:href="pone.0213770.e003.jpg"></graphic><mml:math id="M3"><mml:mi>P</mml:mi><mml:mo>−</mml:mo><mml:mi>v</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>e</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:munderover><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mi>n</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>N</mml:mi><mml:mo>!</mml:mo></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>!</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo><mml:mo>!</mml:mo></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>×</mml:mo><mml:mi>P</mml:mi><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msup><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mi>F</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:math></alternatives></disp-formula></p>
<p>Where n(O) is the observed number of SNV sites within the HERV elements being examined. Bonferroni correction was used to calculate the threshold for the p-Value (0.05/n) (n represents the number of Binomial tests we performed here). The p-value used as our significance cutoff was 8.62e-4 (0.05/58) for the protein coding region nsSNVs (<xref ref-type="supplementary-material" rid="pone.0213770.s006">S4 Table</xref>). For protein non-coding region SNVs in HERVs, the significance cutoff was 1.60e-5 (0.05/3,130) (<xref ref-type="supplementary-material" rid="pone.0213770.s007">S5 Table</xref>).</p>
</sec>
<sec id="sec008">
<title>Differential expression analysis</title>
<p>BioXpress is a gene expression database, which provides differential expression of both gene and miRNA in cancer [<xref ref-type="bibr" rid="pone.0213770.ref039">39</xref>, <xref ref-type="bibr" rid="pone.0213770.ref070">70</xref>]. With respect to a specific cancer type, differential expression analysis using DESeq2 [<xref ref-type="bibr" rid="pone.0213770.ref071">71</xref>] is performed on expression levels of each gene or miRNA in tumor and adjacent non-tumor samples. Current version of BioXpress includes 34 TCGA cancer types (mapped to 73 DOIDs (Cancer Disease Ontology IDs)) [<xref ref-type="bibr" rid="pone.0213770.ref072">72</xref>], in which 20,502 genes and 1,965 miRNAs were analyzed and 18,846 genes and 710 miRNAs have been observed to be significantly differentially expressed in at least one cancer type. Genes of interest (HERVs that overlap with protein coding genes and are somatic mutation hotspots), identified in this study, were further explored in BioXpress to find out if they are significantly overexpressed in cancer.</p>
</sec>
<sec id="sec009">
<title>Survival analysis</title>
<p>Key nsSNVs that were identified were further investigated by log-rank test to evaluate their possible impact on patient survival. Patient clinical information was retrieved from TCGA (<ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link>). Each key nsSNV was retrieved which have significant (p &lt; 0.05) differential expression in the certain cancer types. BioMuta nsSNVs from non-TCGA sources was removed since BioXpress only uses TCGA data. Cancer patients were divided into two groups: one group where the patients have the key nsSNV and the other where they do not. Log-rank test was applied to test the death time distributions for the two groups. The Cox model was used to adjust for factors such as age at initial diagnosis, pathological stage and gender. SAS (version 9.3) using previously published method was used to perform the analysis [<xref ref-type="bibr" rid="pone.0213770.ref073">73</xref>].</p>
</sec>
</sec>
<sec id="sec010" sec-type="results">
<title>Results</title>
<sec id="sec011">
<title>Genome-wide identification of somatic SNVs in HERV elements</title>
<p>In the protein coding region of the human genome 2,867,887 sites impacted by somatic nsSNVs were found. Whereas, in human protein non-coding region, 59,205,289 SNV sites with somatic SNVs were identified (<xref ref-type="supplementary-material" rid="pone.0213770.s008">S6</xref> and <xref ref-type="supplementary-material" rid="pone.0213770.s009">S7</xref> Tables). To confirm the coverage of SNVs in whole human genome, all SNVs were mapped to the genome. <xref ref-type="supplementary-material" rid="pone.0213770.s001">S1 File</xref> shows the distributions of all SNVs in chromosome 1 to 22, X, Y. The gap in the plot represents the repeat sequence and low complexity centromeric region where SNVs are hard to identify.</p>
<p>A total of 2,543 somatic nsSNVs were identified in 25 HERV groups that overlap with human protein coding regions (<xref ref-type="supplementary-material" rid="pone.0213770.s003">S1</xref> and <xref ref-type="supplementary-material" rid="pone.0213770.s008">S6</xref> Tables). Amongst them, 919 nsSNVs were identified in seven Gamma-retrovirus/Epsilon-retrovirus-related (GE) canonical HERV groups. The rest 1,624 nsSNVs were found in 20 non-canonical HERV groups. Ten of the groups were from Gamma-retrovirus /Epsilon-retrovirus-related (GE) non-canonical retrovirus, which involved 50.1% of the total examined nsSNVs. Five out of 20 groups belonging to Alpha-retrovirus/Beta-retrovirus-related (AB) retroviruses contained 23.5% of the nsSNVs. 20.4% of nsSNVs were within two Spumavirus related (S) HERV groups. 5.8% of the nsSNVs were found in the “Uncertain Errantivirus‑like” group and two unclassified HERV groups.</p>
<p>To investigate the distribution of somatic SNVs in HERV elements in protein non-coding regions, we mapped SNVs present in protein non-coding genomic regions HERV genomic coordinates. The results indicate 433,409 human chromosomal non-coding SNVs are located in HERV elements. 167,561 of them (38.7%) were in canonical HERV groups (<xref ref-type="table" rid="pone.0213770.t001">Table 1</xref> and <xref ref-type="supplementary-material" rid="pone.0213770.s009">S7 Table</xref>). Of these 167,561 mutations, 135,032, or 80.8% were found within HERV Gamma-retrovirus/Epsilon-retrovirus-related (GE) retroviruses. 18,295 (10.9%), and 14,243 (8.3%) were found in HERV Alpha-retrovirus/Beta-retrovirus-related (AB) retroviruses, and Spumavirus-related (S) retroviruses, respectively. The rest 265,848 SNVs were found in the non-canonical HERV groups. The non-canonical group classifications are Gamma-retrovirus/Epsilon-retrovirus-related (GE) retroviruses, Alpha-retrovirus/Beta-retrovirus-related (AB) retroviruses, Spumavirus-related (S) retroviruses, Uncertain Errantivirus‑like proviruses, and unclassified groups. The proportion of mutations found in these groups are 72.6% (193,268/265,848), 18.5% (49,324/265,848), 8.3% (22,043/265,848), &lt; 0.001% (89/265,848), and 0.4% (1,124/265,848) respectively (<xref ref-type="supplementary-material" rid="pone.0213770.s009">S7 Table</xref>).</p>
<table-wrap id="pone.0213770.t001" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0213770.t001</object-id>
<label>Table 1</label>
<caption>
<title>Human whole genome SNVs in HERV elements.</title>
</caption>
<alternatives>
<graphic id="pone.0213770.t001g" xlink:href="pone.0213770.t001"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<tbody>
<tr>
<td align="center" colspan="9" rowspan="1">
<bold>Protein Coding region / HERVs</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#E7E7E7">
<bold>HERV sequence</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#E7E7E7">
<bold>Canonical</bold>
</td>
<td align="center" colspan="7" rowspan="1" style="background-color:#E7E7E7">
<bold>Noncanonical</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>HERV supergroups</bold>
</td>
<td align="center" colspan="1" rowspan="1">GE<xref ref-type="table-fn" rid="t001fn001"><sup>a</sup></xref></td>
<td align="center" colspan="1" rowspan="1">GE</td>
<td align="center" colspan="1" rowspan="1">AB<xref ref-type="table-fn" rid="t001fn002"><sup>b</sup></xref></td>
<td align="center" colspan="2" rowspan="1">
<xref ref-type="table-fn" rid="t001fn003">S<sup>c</sup></xref>
</td>
<td align="center" colspan="2" rowspan="1">Uncertain Errantivirus-like proviruses</td>
<td align="center" colspan="1" rowspan="1">Unclassified</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#E7E7E7">
<bold>Total No. of nsSNVs</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#E7E7E7">919</td>
<td align="center" colspan="7" rowspan="1" style="background-color:#E7E7E7">1,624</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>Percentage of nsSNVs</bold>
</td>
<td align="center" colspan="1" rowspan="1">100%</td>
<td align="center" colspan="1" rowspan="1">50.10%</td>
<td align="center" colspan="1" rowspan="1">23.50%</td>
<td align="center" colspan="2" rowspan="1">20.40%</td>
<td align="center" colspan="2" rowspan="1">5.80%</td>
<td align="center" colspan="1" rowspan="1">0.20%</td>
</tr>
<tr>
<td align="center" colspan="9" rowspan="1">
<bold>Non-coding region / HERVs</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#E7E7E7">
<bold>HERV sequence</bold>
</td>
<td align="center" colspan="3" rowspan="1" style="background-color:#E7E7E7">
<bold>Canonical</bold>
</td>
<td align="center" colspan="5" rowspan="1" style="background-color:#E7E7E7">
<bold>Noncanonical</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>HERV supergroups</bold>
</td>
<td align="center" colspan="1" rowspan="1">GE</td>
<td align="center" colspan="1" rowspan="1">AB</td>
<td align="center" colspan="1" rowspan="1">S</td>
<td align="center" colspan="1" rowspan="1">GE</td>
<td align="center" colspan="1" rowspan="1">AB</td>
<td align="center" colspan="1" rowspan="1">S</td>
<td align="center" colspan="1" rowspan="1">Uncertain Errantivirus-like proviruses</td>
<td align="center" colspan="1" rowspan="1">Unclassified</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#E7E7E7">
<bold>Total No. of nsSNVs</bold>
</td>
<td align="center" colspan="3" rowspan="1" style="background-color:#E7E7E7">167,561</td>
<td align="center" colspan="5" rowspan="1" style="background-color:#E7E7E7">265,848</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>Percentage of nsSNVs</bold>
</td>
<td align="center" colspan="1" rowspan="1">80.80%</td>
<td align="center" colspan="1" rowspan="1">10.90%</td>
<td align="center" colspan="1" rowspan="1">8.30%</td>
<td align="center" colspan="1" rowspan="1">72.60%</td>
<td align="center" colspan="1" rowspan="1">18.50%</td>
<td align="center" colspan="1" rowspan="1">8.30%</td>
<td align="center" colspan="1" rowspan="1">&lt; 0.001%</td>
<td align="center" colspan="1" rowspan="1">0.40%</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001">
<p><sup>a</sup> Gamma-retrovirus/Epsilon-retrovirus-related</p>
</fn>
<fn id="t001fn002">
<p><sup>b</sup> Alpha-retrovirus/ Beta-retrovirus-related</p>
</fn>
<fn id="t001fn003">
<p><sup>c</sup> Spumavirus-related</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec012">
<title>Somatic SNV hotspots in HERV elements</title>
<p>To understand whether certain HERV elements contain a significantly different number of SNVs than expected, we compared the observed mutations within each HERV element to expected number of mutations.</p>
<sec id="sec013">
<title>SNVs from human protein coding region with HERV elements</title>
<p>There are several HERV elements that overlap with the exon of genes. We identified HERVs which contained significantly more nsSNVs than expected (p &lt; 8.62e-4). There were 83 HERVs with 2,543 nsSNVs (<xref ref-type="fig" rid="pone.0213770.g001">Fig 1A</xref>). 39% of the elements (32/83), encompassing 1,855 of the 2,543 nsSNVs, have significant numbers of nsSNVs (<xref ref-type="supplementary-material" rid="pone.0213770.s006">S4 Table</xref>). Majority of the HERV elements (28/32, 87.5%) are in 18 different HERV groups, and of these, 28 HERVs have significantly fewer nsSNVs than expected in the protein coding region. The remaining 4 (12.5%) HERV elements include significant over-representation of nsSNVs (<xref ref-type="table" rid="pone.0213770.t002">Table 2</xref> and <xref ref-type="supplementary-material" rid="pone.0213770.s010">S8 Table</xref>) containing 492 of the 1,855 (26%) and hence was prioritized for further functional analysis. In total, 492 nsSNVs are concentrated in the exon regions of 4 genes: tenascin N (TNN) (with HERV-9/LTR12) (p = 6.67e-4), zinc finger protein 99 (ZNF99) (with HERV-W/HERV17/LTR17) (2.63e-26), killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1) (with MaLR/MST) (3.26e-7), and olfactory receptor family 4 subfamily K member 15 (OR4K15) (with HERV-IP10F/LTR10F) (2.58e-5) (<xref ref-type="table" rid="pone.0213770.t002">Table 2</xref>, <xref ref-type="supplementary-material" rid="pone.0213770.s010">S8</xref> and <xref ref-type="supplementary-material" rid="pone.0213770.s011">S9</xref> Tables).</p>
<fig id="pone.0213770.g001" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0213770.g001</object-id>
<label>Fig 1</label>
<caption>
<title>SNVs within HERV elements on human protein coding and protein non-coding regions.</title>
<p>(A) nsSNVs in HERV elements on the human protein coding region by chromosome. The X-axis represents chromosomes while the Y-axis shows the transformed (-log10[P]) P-value. The transformed P-value was used to obtain the specific HERV elements with significant representation of nsSNVs. The threshold is 4.06 (-Log10 (8.62e-4)). Each dot on the Manhattan plot represent one HERV element; the different colors interprets the HERV element in a different chromosome. If the HERV element contains significantly more nsSNVs than expected nsSNVs, the HERV element is interpreted with a significant over-representation of nsSNVs. Approximately 42% HERV elements have a significant over-representation of nsSNVs. (B) SNVs in HERV elements on human non-coding region by chromosome. The threshold is 4.80 (-Log10 (1.60e-5)).</p>
</caption>
<graphic xlink:href="pone.0213770.g001"></graphic>
</fig>
<table-wrap id="pone.0213770.t002" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0213770.t002</object-id>
<label>Table 2</label>
<caption>
<title>Four HERV elements with significantly over-represented nsSNVs mapped to four genes.</title>
</caption>
<alternatives>
<graphic id="pone.0213770.t002g" xlink:href="pone.0213770.t002"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">HERV Sequence</th>
<th align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">HERV ID</th>
<th align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">HERV groups</th>
<th align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">Gene</th>
<th align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">Chromosome</th>
<th align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">Length</th>
<th align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">Mutations</th>
<th align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">Expected mutations</th>
<th align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">Difference</th>
<th align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>Non-canon</bold>
</td>
<td align="center" colspan="1" rowspan="1">6114</td>
<td align="center" colspan="1" rowspan="1">HERV-9/<break></break>LTR12</td>
<td align="center" colspan="1" rowspan="1">TNN</td>
<td align="center" colspan="1" rowspan="1">1</td>
<td align="center" colspan="1" rowspan="1">264</td>
<td align="center" colspan="1" rowspan="1">35</td>
<td align="center" colspan="1" rowspan="1">20.47</td>
<td align="center" colspan="1" rowspan="1">14.52</td>
<td align="center" colspan="1" rowspan="1">6.67e-04</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>Non-canon</bold>
</td>
<td align="center" colspan="1" rowspan="1">4780</td>
<td align="center" colspan="1" rowspan="1">MST/<break></break>MaLR</td>
<td align="center" colspan="1" rowspan="1">KIR2DL1</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">702</td>
<td align="center" colspan="1" rowspan="1">92</td>
<td align="center" colspan="1" rowspan="1">54.43</td>
<td align="center" colspan="1" rowspan="1">37.56</td>
<td align="center" colspan="1" rowspan="1">3.26e-07</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>Non-canon</bold>
</td>
<td align="center" colspan="1" rowspan="1">4062</td>
<td align="center" colspan="1" rowspan="1">HERV-IP10F/<break></break>LTR10F</td>
<td align="center" colspan="1" rowspan="1">OR4K15</td>
<td align="center" colspan="1" rowspan="1">14</td>
<td align="center" colspan="1" rowspan="1">1044</td>
<td align="center" colspan="1" rowspan="1">116</td>
<td align="center" colspan="1" rowspan="1">80.95</td>
<td align="center" colspan="1" rowspan="1">35.04</td>
<td align="center" colspan="1" rowspan="1">2.58e-05</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>Non-canon</bold>
</td>
<td align="center" colspan="1" rowspan="1">4673</td>
<td align="center" colspan="1" rowspan="1">HERV-W/<break></break>LTR17/<break></break>HERV17</td>
<td align="center" colspan="1" rowspan="1">ZNF99</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">1585</td>
<td align="center" colspan="1" rowspan="1">249</td>
<td align="center" colspan="1" rowspan="1">122.91</td>
<td align="center" colspan="1" rowspan="1">126.08</td>
<td align="center" colspan="1" rowspan="1">2.63e-26</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec014">
<title>SNVs from human protein non-coding regions mapping to HERV elements</title>
<p>There are 1,820 HERV elements in protein non-coding regions which contain significant over- or under-representation of SNVs (<xref ref-type="fig" rid="pone.0213770.g001">Fig 1B</xref> and <xref ref-type="supplementary-material" rid="pone.0213770.s007">S5 Table</xref>) (p &lt; 1.60e-5). Most of the HERV elements (1,032 or 57%) have significantly fewer mutations than expected. The remaining 788 HERV elements (43%) have an over-representation of SNVs, which account for more than 73% of the total SNVs. 193,439 SNVs (<xref ref-type="supplementary-material" rid="pone.0213770.s007">S5</xref> and <xref ref-type="supplementary-material" rid="pone.0213770.s012">S10</xref> Tables) were identified in 788 HERV elements that contained a significantly high number of mutations (p &lt; 1.60e-5). The proportion of somatic mutations in canonical HERVs (41.7%) is lower than that of non-canonical HERVs (58.3%). For canonical HERVs, the proportion of somatic mutations in Gamma-retrovirus/Epsilon-retrovirus-related (GE) retroviruses, Alpha-retrovirus/Beta-retrovirus-related (AB) retroviruses, Spumavirus-related (S) retroviruses HERV groups are 80.9%, 9.3%, 9.8%, respectively. For non-canonical HERVs, the proportion of mutations in classes Gamma-retrovirus/Epsilon-retrovirus-related (GE) retroviruses, Alpha-retrovirus/Beta-retrovirus-related (AB) retroviruses, Spumavirus-related (S) retroviruses are 72.9%, 17.3%, and 9.8% respectively.</p>
</sec>
</sec>
<sec id="sec015">
<title>Genome-wide pan-cancer analysis</title>
<sec id="sec016">
<title>HERV elements with over-representation of nsSNVs</title>
<p>To further investigate the impact of nsSNVs in HERV regions in different cancer types, cancer terms were unified using cancer disease ontology (DO) [<xref ref-type="bibr" rid="pone.0213770.ref072">72</xref>]. The relationship between nsSNVs in the protein coding region HERV elements and multiple cancer types is shown in <xref ref-type="fig" rid="pone.0213770.g002">Fig 2</xref>. It can be seen from <xref ref-type="table" rid="pone.0213770.t002">Table 2</xref> that 81.3% of the nsSNVs are from Gamma-retrovirus/Epsilon-retrovirus-related (GE) non-canonical HERV elements (HERV-W/LTR17/HERV17, HERV-9/LTR12 and HERV-IP10F/LTR10F). These nsSNVs are associated with at least 20 cancer types. The top three cancer types—skin cancer, lung cancer, and colon cancer—are associated with mutated sites in HERV-W/LTR17/HERV17. The proportion of mutations in HERV-W/LTR17/HERV17 was 50.6% (249/492). HERV element in Spumavirus-related (S) (MaLR/MST) is found in several cancer types. The proportion of mutations in (MaLR/MST) was 18.7% (92/492). This set of MaLR/MST mutations is found in many cancer types including skin cancer, thyroid cancer, and lung cancer.</p>
<fig id="pone.0213770.g002" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0213770.g002</object-id>
<label>Fig 2</label>
<caption>
<title>The relationship between HERV elements on the human protein coding regions with over-represented nsSNVs and multiple cancers.</title>
<p>The CIRCOS plot represents the number of nsSNVs in each HERV element that are found in multiple cancer types. The Gamma-retrovirus/Epsilon-retrovirus-related non-canonical HERV elements which contain HERV-W/LTR17/HERV17, HERV-IP10F/LTR10F, and HERV-9/LTR12 include 81.6% nsSNVs. The Gamma-retrovirus/Epsilon-retrovirus-related non-canonical HERV elements are associated with top cancer types including skin cancer, lung cancer, and head &amp; neck cancer. The proportion of nsSNVs in MST/MaLR, Spumavirus-related non-canonical HERV elements, is close to 18%, which associated with top cancer types including skin cancer, thyroid cancer, and lung cancer. Please note that all HERVs nomenclatures are presented by supergroups and see their relative/similar element in <xref ref-type="supplementary-material" rid="pone.0213770.s004">S2 Table</xref>.</p>
</caption>
<graphic xlink:href="pone.0213770.g002"></graphic>
</fig>
</sec>
<sec id="sec017">
<title>HERV elements with an over-representation of SNVs from protein non-coding regions</title>
<p>SNVs in the human chromosomal non-coding region of HERV elements could also lead to carcinogenesis if they impact regulatory regions or protein binding sites [<xref ref-type="bibr" rid="pone.0213770.ref074">74</xref>]. Liang et. al. suggested the HERV elements with unstable genomic variants near lncRNA can trigger onset of human adenocarcinoma [<xref ref-type="bibr" rid="pone.0213770.ref075">75</xref>]. Based on our results (<xref ref-type="fig" rid="pone.0213770.g001">Fig 1B</xref>), we identified 788 HERV elements with significant over-representation of SNVs. <xref ref-type="supplementary-material" rid="pone.0213770.s002">S1 Fig</xref> indicates each of 788 HERV elements contains 144 SNVs on average, which are coming from skin cancer patient samples. The second highest number (29 SNVs on average) is from esophageal cancer. And the third highest number is from liver cancer (15 SNVs on average).</p>
<p><xref ref-type="fig" rid="pone.0213770.g003">Fig 3</xref> shows the distribution of SNVs in 357 canonical and 431 non-canonical HERV elements that map to protein non-coding regions. In both canonical (<xref ref-type="fig" rid="pone.0213770.g003">Fig 3A</xref>) and non-canonical (<xref ref-type="fig" rid="pone.0213770.g003">Fig 3B</xref>) Gamma-retrovirus/Epsilon-retrovirus-related (GE) HERVs, HERV-H/LTR7 and HERV-9/LTR12 contain the largest numbers of SNVs from skin cancer, esophageal cancer, and breast cancer. In canonical Alpha-retrovirus/Beta-retrovirus-related (AB) HERVs, HML-8/HERV-K11I/MER11A contain the most somatic mutations. HML-3/HERV-K9I/MER9 is the most affected non-canonical Alpha-retrovirus/Beta-retrovirus-related (AB) HERVs. In both canonical and non-canonical Spumavirus-related (S) HERVs, HERV-L/LTR7 has the highest SNV sites.</p>
<fig id="pone.0213770.g003" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0213770.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Canonical and non-canonical HERVs on human non-coding region and their relationships with cancer.</title>
<p>(A) the relationship between 357 canonical HERV element on human non-coding region and cancers. The CIRCOS plot shows the number of SNVs in each canonical HERV element within human non-coding region and how they are associated with multiple cancer types. The proportion of Gamma-retrovirus/Epsilon-retrovirus-related canonical HERV elements which includes HERV-H/LTR7, HERV-9/LTR12, HERV-IP10F/LTR10F and HUERSP/MER52/LTR25 is close 60%. They are associated with multiple cancer types including skin cancer, esophageal cancer, and breast cancer. The proportion of Alpha-retrovirus/ Beta-retrovirus-related canonical HERV elements which includes HML-8/HERVK11I/MER11A is close 42%. They are associated with multiple cancer types including skin cancer. The proportion of Spumavirus-related canonical HERV elements which includes HERV-L/MLT2 is close 93.7%. They are associated with multiple cancer types including skin cancer. (B) the relationship between 431 non-canonical HERV element on human non-coding region and cancers. The CIRCOS plot shows the number of SNVs in each non-canonical HERV element within non-coding region and how they are associated with multiple cancer types. The proportion of Gamma-retrovirus/Epsilon-retrovirus-related non-canonical HERV elements which includes HERVH/LTR7, HERV9/LTR12 and HERV-IP10F/LTR10F is close 63% and their association with multiple cancer types including skin cancer, esophageal cancer, and breast cancer. The proportion of Alpha-retrovirus/ Beta-retrovirus-related canonical HERV elements which includes HML-3/HERVK9I/MER9 is close to 37%. The proportion of Spumavirus-related canonical HERV elements which includes HERV-L/MLT2 is close to 62.7%. They are found in multiple cancer types including skin cancer. Please note that all HERVs nomenclatures are presented by supergroups and see their relative/similar element in <xref ref-type="supplementary-material" rid="pone.0213770.s004">S2 Table</xref> and that three HERVs minor supergroups (MER52, THE, and HARLEQUIN) which present in the <xref ref-type="fig" rid="pone.0213770.g003">Fig 3</xref> are listed in <xref ref-type="supplementary-material" rid="pone.0213770.s004">S2 Table</xref>.</p>
</caption>
<graphic xlink:href="pone.0213770.g003"></graphic>
</fig>
</sec>
</sec>
<sec id="sec018">
<title>Functional analyses</title>
<sec id="sec019">
<title>Expression of genes containing HERV element with over-represented nsSNVs</title>
<p>Even though the nsSNVs in our dataset are somatic mutations, the correlation between gene expression, HERVs, and each cancer type can provide insights into the role of these genes in cancer. Our results show that nsSNVs found in multiple cancer types are located within exomes of <italic>TNN</italic>, <italic>KIR2DL1</italic>, <italic>OR4K15</italic>, and <italic>ZNF99</italic> genes. We examined whether or not their differential expression were significant in 34 cancer types.</p>
<p>We found that <italic>TNN</italic> was significantly over-expressed in kidney renal clear cell carcinoma (KIRC) (p = 0.024) and prostate cancer (p ≈0), but significantly under-expressed in liver (p = 0.003) and breast cancer (p = 0.003). 68% (49/72) of patients with KIRC and 84.6% (44/52) of patients with prostate cancer have the same trend of over-expressed <italic>TNN</italic> (<xref ref-type="fig" rid="pone.0213770.g004">Fig 4</xref>). Conversely, 88% (44/50) of patients with liver cancer and 54.4% (62/114) of patients with breast cancer have a similar tendency of under-expressed <italic>TNN</italic>. Additionally, <italic>KIR2DL1</italic> was significantly over-expressed in kidney cancer (p ≈0) while significantly under-expressed in lung cancer (p ≈0). 91.7% (66/72) patients had a positive correlation of up-regulated <italic>KIR2DL1</italic> in kidney cancer. 94.1% (48/51) patients had a direct correlation of down-regulated <italic>KIR2DL1</italic> in lung cancer (<xref ref-type="fig" rid="pone.0213770.g004">Fig 4</xref>). Moreover, <italic>ZNF99</italic> was significantly under-expressed in kidney cancer (p ≈0). 84.72% (61/72) of patients with kidney have the same trend of under-expression of <italic>ZNF99</italic> in kidney cancer (<xref ref-type="fig" rid="pone.0213770.g004">Fig 4</xref>).</p>
<fig id="pone.0213770.g004" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0213770.g004</object-id>
<label>Fig 4</label>
<caption>
<title>The differential expression of four key genes identified in this study across multiple cancers.</title>
<p>X-axis is the gene name from left to right (ZNF99, OR4K15, TNN, KIR2DL1). Y-axis is cancer type. Cancer types are as reported by TCGA from top to bottom: SARC (Sarcoma), PRAD (Prostate adenocarcinoma), PAAD (Pancreatic adenocarcinoma), BLCA (Bladder Urothelial Carcinoma), UCEC (Uterine Corpus Endometrial Carcinoma), READ (Rectum adenocarcinoma), COAD (Colon adenocarcinoma), LUAD (Lung adenocarcinoma), STAD (Stomach adenocarcinoma), KICH (Kidney Chromophobe), THCA (Thyroid carcinoma), HNSC (Head and Neck squamous cell carcinoma), LIHC (Liver hepatocellular carcinoma), BRCA (Breast invasive carcinoma), KIRP (Kidney renal papillary cell carcinoma), LUSC (Lung squamous cell carcinoma), KIRC (Kidney renal clear cell carcinoma), ESCA (Esophageal carcinoma), and CESC (Cervical squamous cell carcinoma and endocervical adenocarcinoma). The heatmap represents the differential expressions across multiple cancers. Red represents the level of over-expression of the gene. Green represents the level of under-expression of the gene. The value of differential expression was calculated by Log2Fold-Change.</p>
</caption>
<graphic xlink:href="pone.0213770.g004"></graphic>
</fig>
</sec>
<sec id="sec020">
<title>SNVs impact on HERV region and protein functional sites</title>
<p>In addition to our gene expression analysis, we counted the numbers of nsSNVs that may have an impact on functional sites within these four genes. <xref ref-type="supplementary-material" rid="pone.0213770.s013">S11 Table</xref> provides the total number of nsSNVs affecting post-translational modification of amino acids. In the gene <italic>TNN</italic>, cancer-associated nsSNVs within HERV elements were found to likely impact amino acid post-translational modification (PTM) sites that led to phosphorylation gain or loss. In <italic>KIR2DL1</italic>, mutations were found to likely impact multiple functions such as phosphorylation, glycosylation, and ligand binding site. In <italic>OR4K15</italic> and <italic>ZNF99</italic>, nsSNVs affect the modification of amino acid phosphorylation and glycosylation.</p>
<p>We combined the results of nsSNVs found in cancers with significant differential gene expression data and impacted PTM sites (<xref ref-type="table" rid="pone.0213770.t003">Table 3</xref>). Three nsSNVs in TNN are found in kidney cancer and breast cancer samples. One of these three nsSNVs impacts a PTM site of the protein. 12 nsSNVs in <italic>KIR2DL1</italic> are found in lung cancer and kidney cancer samples. Six out of these 12 nsSNVs affect PTM sites on this protein. In <italic>ZNF99</italic>, seven nsSNVs are found in kidney cancer and there are no PTM site affecting nsSNVs.</p>
<table-wrap id="pone.0213770.t003" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0213770.t003</object-id>
<label>Table 3</label>
<caption>
<title>22 nsSNVs in the four significantly differentially expressed of genes and their functional sites.</title>
</caption>
<alternatives>
<graphic id="pone.0213770.t003g" xlink:href="pone.0213770.t003"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="1" rowspan="1">Gene</th>
<th align="center" colspan="1" rowspan="1">Chromo<break></break>some</th>
<th align="center" colspan="1" rowspan="1">Position_<break></break>N<xref ref-type="table-fn" rid="t003fn001"><sup>a</sup></xref></th>
<th align="center" colspan="1" rowspan="1">Ref_<break></break>N<xref ref-type="table-fn" rid="t003fn002"><sup>b</sup></xref></th>
<th align="center" colspan="1" rowspan="1">Var_<break></break>N<xref ref-type="table-fn" rid="t003fn003"><sup>c</sup></xref></th>
<th align="center" colspan="1" rowspan="1">Position_<break></break>A<xref ref-type="table-fn" rid="t003fn004"><sup>d</sup></xref></th>
<th align="center" colspan="1" rowspan="1">Ref_<break></break>A<xref ref-type="table-fn" rid="t003fn005"><sup>e</sup></xref></th>
<th align="center" colspan="1" rowspan="1">Var_<break></break>A<xref ref-type="table-fn" rid="t003fn006"><sup>f</sup></xref></th>
<th align="center" colspan="1" rowspan="1">Predicted impact on function</th>
<th align="center" colspan="1" rowspan="1">DOID /Cancer type</th>
<th align="center" colspan="1" rowspan="1">HERV<break></break>_Id</th>
<th align="center" colspan="1" rowspan="1">HERV group</th>
<th align="center" colspan="1" rowspan="1">HERV Supergroup</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">
<bold>TNN</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">1</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">2061</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">C</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">A</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">687</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">H</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">Q</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">-</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">DOID:1612 / breast cancer</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">6114</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">HERV-9/<break></break>LTR12</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">GE<xref ref-type="table-fn" rid="t003fn007"><sup>g</sup></xref></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>TNN</bold>
</td>
<td align="center" colspan="1" rowspan="1">1</td>
<td align="center" colspan="1" rowspan="1">2062</td>
<td align="center" colspan="1" rowspan="1">G</td>
<td align="center" colspan="1" rowspan="1">A</td>
<td align="center" colspan="1" rowspan="1">688</td>
<td align="center" colspan="1" rowspan="1">V</td>
<td align="center" colspan="1" rowspan="1">M</td>
<td align="center" colspan="1" rowspan="1">-</td>
<td align="center" colspan="1" rowspan="1">DOID:1612 / breast cancer</td>
<td align="center" colspan="1" rowspan="1">6114</td>
<td align="center" colspan="1" rowspan="1">HERV-9/<break></break>LTR12</td>
<td align="center" colspan="1" rowspan="1">GE</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">
<bold>TNN</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">1</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">1991</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">T</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">C</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">664</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">V</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">A</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">Gain|<break></break>Phosphorylation</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">DOID:263 / kidney cancer</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">6114</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">HERV-9/<break></break>LTR12</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">GE</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>KIR2DL1</bold>
</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">64</td>
<td align="center" colspan="1" rowspan="1">C</td>
<td align="center" colspan="1" rowspan="1">A</td>
<td align="center" colspan="1" rowspan="1">22</td>
<td align="center" colspan="1" rowspan="1">H</td>
<td align="center" colspan="1" rowspan="1">N</td>
<td align="center" colspan="1" rowspan="1">Gain|<break></break>Phosphorylation</td>
<td align="center" colspan="1" rowspan="1">DOID:1324 / lung cancer</td>
<td align="center" colspan="1" rowspan="1">4780</td>
<td align="center" colspan="1" rowspan="1">MST/<break></break>MaLR</td>
<td align="center" colspan="1" rowspan="1">
<xref ref-type="table-fn" rid="t003fn008">S<sup>h</sup></xref>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">
<bold>KIR2DL1</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">19</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">95</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">T</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">C</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">32</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">L</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">P</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">-</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">DOID:1324 / lung cancer</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">4780</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">MST/<break></break>MaLR</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">S</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>KIR2DL1</bold>
</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">328</td>
<td align="center" colspan="1" rowspan="1">C</td>
<td align="center" colspan="1" rowspan="1">T</td>
<td align="center" colspan="1" rowspan="1">110</td>
<td align="center" colspan="1" rowspan="1">Q</td>
<td align="center" colspan="1" rowspan="1">X</td>
<td align="center" colspan="1" rowspan="1">-</td>
<td align="center" colspan="1" rowspan="1">DOID:1324 / lung cancer</td>
<td align="center" colspan="1" rowspan="1">4780</td>
<td align="center" colspan="1" rowspan="1">MST/<break></break>MaLR</td>
<td align="center" colspan="1" rowspan="1">S</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">
<bold>KIR2DL1</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">19</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">55</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">G</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">T</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">19</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">A</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">S</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">-</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">DOID:1324 / lung cancer</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">4780</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">MST/<break></break>MaLR</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">S</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>KIR2DL1</bold>
</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">487</td>
<td align="center" colspan="1" rowspan="1">G</td>
<td align="center" colspan="1" rowspan="1">T</td>
<td align="center" colspan="1" rowspan="1">163</td>
<td align="center" colspan="1" rowspan="1">E</td>
<td align="center" colspan="1" rowspan="1">X</td>
<td align="center" colspan="1" rowspan="1">-</td>
<td align="center" colspan="1" rowspan="1">DOID:1324 / lung cancer</td>
<td align="center" colspan="1" rowspan="1">4780</td>
<td align="center" colspan="1" rowspan="1">MST/<break></break>MaLR</td>
<td align="center" colspan="1" rowspan="1">S</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">
<bold>KIR2DL1</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">19</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">506</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">G</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">A</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">169</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">R</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">H</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">-</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">DOID:1324 / lung cancer</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">4780</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">MST/<break></break>MaLR</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">S</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>KIR2DL1</bold>
</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">308</td>
<td align="center" colspan="1" rowspan="1">C</td>
<td align="center" colspan="1" rowspan="1">A</td>
<td align="center" colspan="1" rowspan="1">103</td>
<td align="center" colspan="1" rowspan="1">S</td>
<td align="center" colspan="1" rowspan="1">Y</td>
<td align="center" colspan="1" rowspan="1">Gain|<break></break>Phosphorylation</td>
<td align="center" colspan="1" rowspan="1">DOID:1324 / lung cancer</td>
<td align="center" colspan="1" rowspan="1">4780</td>
<td align="center" colspan="1" rowspan="1">MST/<break></break>MaLR</td>
<td align="center" colspan="1" rowspan="1">S</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">
<bold>KIR2DL1</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">19</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">310</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">G</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">C</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">104</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">V</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">L</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">Gain|<break></break>Phosphorylation</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">DOID:263 / kidney cancer</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">4780</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">MST/<break></break>MaLR</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">S</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>KIR2DL1</bold>
</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">487</td>
<td align="center" colspan="1" rowspan="1">G</td>
<td align="center" colspan="1" rowspan="1">A</td>
<td align="center" colspan="1" rowspan="1">163</td>
<td align="center" colspan="1" rowspan="1">E</td>
<td align="center" colspan="1" rowspan="1">K</td>
<td align="center" colspan="1" rowspan="1">-</td>
<td align="center" colspan="1" rowspan="1">DOID:263 / kidney cancer</td>
<td align="center" colspan="1" rowspan="1">4780</td>
<td align="center" colspan="1" rowspan="1">MST/<break></break>MaLR</td>
<td align="center" colspan="1" rowspan="1">S</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">
<bold>KIR2DL1</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">19</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">608</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">A</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">G</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">203</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">H</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">R</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">Gain|<break></break>Phosphorylation</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">DOID:1324 / lung cancer</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">4780</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">MST/<break></break>MaLR</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">S</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>KIR2DL1</bold>
</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">670</td>
<td align="center" colspan="1" rowspan="1">C</td>
<td align="center" colspan="1" rowspan="1">A</td>
<td align="center" colspan="1" rowspan="1">224</td>
<td align="center" colspan="1" rowspan="1">P</td>
<td align="center" colspan="1" rowspan="1">T</td>
<td align="center" colspan="1" rowspan="1">Gain|<break></break>Glycosylation</td>
<td align="center" colspan="1" rowspan="1">DOID:1324 / lung cancer</td>
<td align="center" colspan="1" rowspan="1">4780</td>
<td align="center" colspan="1" rowspan="1">MST/<break></break>MaLR</td>
<td align="center" colspan="1" rowspan="1">S</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">
<bold>KIR2DL1</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">19</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">680</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">G</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">T</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">227</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">S</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">I</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">Gain|<break></break>Glycosylation</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">DOID:1324 / lung cancer</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">4780</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">MST/<break></break>MaLR</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">S</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>ZNF99</bold>
</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">1858</td>
<td align="center" colspan="1" rowspan="1">C</td>
<td align="center" colspan="1" rowspan="1">G</td>
<td align="center" colspan="1" rowspan="1">620</td>
<td align="center" colspan="1" rowspan="1">P</td>
<td align="center" colspan="1" rowspan="1">A</td>
<td align="center" colspan="1" rowspan="1">-</td>
<td align="center" colspan="1" rowspan="1">DOID:263 / kidney cancer</td>
<td align="center" colspan="1" rowspan="1">4673</td>
<td align="center" colspan="1" rowspan="1">HERV-W/<break></break>LTR17/<break></break>HERV17</td>
<td align="center" colspan="1" rowspan="1">GE</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">
<bold>ZNF99</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">19</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">2272</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">G</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">C</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">758</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">E</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">Q</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">-</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">DOID:263 / kidney cancer</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">4673</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">HERV-W/<break></break>LTR17/<break></break>HERV17</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">GE</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>ZNF99</bold>
</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">2338</td>
<td align="center" colspan="1" rowspan="1">A</td>
<td align="center" colspan="1" rowspan="1">G</td>
<td align="center" colspan="1" rowspan="1">780</td>
<td align="center" colspan="1" rowspan="1">K</td>
<td align="center" colspan="1" rowspan="1">E</td>
<td align="center" colspan="1" rowspan="1">-</td>
<td align="center" colspan="1" rowspan="1">DOID:263 / kidney cancer</td>
<td align="center" colspan="1" rowspan="1">4673</td>
<td align="center" colspan="1" rowspan="1">HERV-W/<break></break>LTR17/<break></break>HERV17</td>
<td align="center" colspan="1" rowspan="1">GE</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">
<bold>ZNF99</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">19</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">1557</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">G</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">C</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">519</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">K</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">N</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">-</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">DOID:263 / kidney cancer</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">4673</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">HERV-W/<break></break>LTR17/<break></break>HERV17</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">GE</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>ZNF99</bold>
</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">1630</td>
<td align="center" colspan="1" rowspan="1">A</td>
<td align="center" colspan="1" rowspan="1">T</td>
<td align="center" colspan="1" rowspan="1">544</td>
<td align="center" colspan="1" rowspan="1">K</td>
<td align="center" colspan="1" rowspan="1">X</td>
<td align="center" colspan="1" rowspan="1">-</td>
<td align="center" colspan="1" rowspan="1">DOID:263 / kidney cancer</td>
<td align="center" colspan="1" rowspan="1">4673</td>
<td align="center" colspan="1" rowspan="1">HERV-W/<break></break>LTR17/<break></break>HERV17</td>
<td align="center" colspan="1" rowspan="1">GE</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">
<bold>ZNF99</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">19</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">2270</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">C</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">G</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">757</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">A</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">G</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">-</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">DOID:263 / kidney cancer</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">4673</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">HERV-W/<break></break>LTR17/<break></break>HERV17</td>
<td align="center" colspan="1" rowspan="1" style="background-color:#C0C0C0">GE</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
<bold>ZNF99</bold>
</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">1582</td>
<td align="center" colspan="1" rowspan="1">A</td>
<td align="center" colspan="1" rowspan="1">C</td>
<td align="center" colspan="1" rowspan="1">528</td>
<td align="center" colspan="1" rowspan="1">K</td>
<td align="center" colspan="1" rowspan="1">Q</td>
<td align="center" colspan="1" rowspan="1">-</td>
<td align="center" colspan="1" rowspan="1">DOID:263 / kidney cancer</td>
<td align="center" colspan="1" rowspan="1">4673</td>
<td align="center" colspan="1" rowspan="1">HERV-W/<break></break>LTR17/<break></break>HERV17</td>
<td align="center" colspan="1" rowspan="1">GE</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001">
<p><sup>a</sup> Position of nucleotide</p>
</fn>
<fn id="t003fn002">
<p><sup>b</sup> Reference of nucleotide</p>
</fn>
<fn id="t003fn003">
<p><sup>c</sup> Variant of nucleotide</p>
</fn>
<fn id="t003fn004">
<p><sup>d</sup> Position of amino acid</p>
</fn>
<fn id="t003fn005">
<p><sup>e</sup> Reference of amino acid</p>
</fn>
<fn id="t003fn006">
<p><sup>f</sup> Variant of nucleotide</p>
</fn>
<fn id="t003fn007">
<p><sup>g</sup> Gamma-retrovirus/Epsilon-retrovirus-related</p>
</fn>
<fn id="t003fn008">
<p><sup>h</sup> Spumavirus-related</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec021">
<title>Survival analysis on 22 key nsSNV in cancer patients</title>
<p>The total number of nsSNVs in genes which showed significant differential expression in cancer tissues compared to non-tumor tissues were 22 (<xref ref-type="table" rid="pone.0213770.t003">Table 3</xref>). After extracting metadata and clinical data for patients for these 22 nsSNVs, we found one SNV in <italic>ZNF99</italic> to be associated closely with patient survival rate, as shown in <xref ref-type="fig" rid="pone.0213770.g005">Fig 5</xref>.</p>
<fig id="pone.0213770.g005" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0213770.g005</object-id>
<label>Fig 5</label>
<caption>
<title>The survival rate in the kidney cancer patients with or without the nsSNV at genomic position 2270 (C to G modification) of ZNF99.</title>
<p>Kaplan-Meier plot of kidney cancer patient survival based on the existence of ZNF99 (C2270G). X-axis indicate days of survival. Y-axis indicates survival probability. Red and blue lines indicate survival time of kidney cancer patients with and without such mutation respectively. Log-rank test shows that, comparing with patients with ZNF99(C2270G), patients without this nsSNV survive longer with adjusted p-value of 0.05. The hazard ratio is 2.642.</p>
</caption>
<graphic xlink:href="pone.0213770.g005"></graphic>
</fig>
<p>As shown in <xref ref-type="fig" rid="pone.0213770.g005">Fig 5</xref>, patients with this nsSNV in <italic>ZNF99</italic> at amino acid position 757 (A to G modification) have a lower survival rate than the patients without this variation. This key amino acid located in position 757 of ZNF99, which triggers abnormal significant under-expression of <italic>ZNF99</italic> in kidney cancer. Additionally, the kidney cancer patients with this key mutation in <italic>ZNF99</italic> have a significant decrease in survival rate (Hazard ratio = 2.642; p = 0.05). We believe this nsSNV could be involved in the progression of cancer and further analysis is warranted to validate this mutation.</p>
</sec>
</sec>
<sec id="sec022">
<title>Distribution of SNVs in HERVs from human protein non-coding regions that overlap with DNA functional elements</title>
<p>To investigate the potential functional roles of the HERV elements from protein non-coding regions, with over-represented mutations, we mapped them to our DNA functional elements dataset. We found that 62,575 variants occur in both HERV elements and in at least one DNA functional element (<xref ref-type="fig" rid="pone.0213770.g006">Fig 6</xref>). In our results (<xref ref-type="fig" rid="pone.0213770.g006">Fig 6</xref> and <xref ref-type="supplementary-material" rid="pone.0213770.s014">S12 Table</xref>), the proportion of SNVs within lncRNA, intron, and TFBS is over 97% of all functionally affected SNVs. The top functional element is long non-coding RNA (lncRNA) which contains 60% of these variants. Additionally, other highly represented functional elements are intron (22.2%), transcription factor binding site (TFBS) (15%), alternative splice site (AS) (1.7%), pseudo exon (PE) (0.27%), and CpG Island (0.2%).</p>
<fig id="pone.0213770.g006" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0213770.g006</object-id>
<label>Fig 6</label>
<caption>
<title>HERV elements on human non-coding region with over-represented SNVs distributed to DNA functional elements.</title>
<p>X-axis is different DNA functional elements. Y-axis is Log2Counts (Counts mean the number of SNVs). The proportion of SNVs on DNA functional elements are LncRNA (long non-coding RNA) (60%), Intron (22.2%), TFBS (transcription factor binding site) (15%), AS (alternative splice site) (1.7%), PE (pseudo exon) (0.27%), and CpG (CpG Island) (0.2%).</p>
</caption>
<graphic xlink:href="pone.0213770.g006"></graphic>
</fig>
<p>Cancer and HERV associations were further explored in lncRNA, intron, and TFBS. <xref ref-type="fig" rid="pone.0213770.g007">Fig 7</xref> shows that, HERV mutations in lncRNAs are found in multiple cancers, especially, skin and esophageal cancer. Additionally, HERV mutation hotspots in introns are from at least 10 cancer types. HERV mutations in TFBS is primarily found in skin cancer and breast cancer; especially, the non-canonical Gamma-retrovirus/Epsilon-retrovirus-related (GE) HERV in the TFBS. This study provides a direction to narrow down the HERVs in well-defined DNA functional elements which potentially could play a role in cancer.</p>
<fig id="pone.0213770.g007" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0213770.g007</object-id>
<label>Fig 7</label>
<caption>
<title>The correlation between HERV-involved DNA functional elements and cancers.</title>
<p>Y-axis indicates the SNVs within each HERV class located on each DNA functional elements from top to bottom: SNVs located on HERV elements and DNA functional elements which have combinations containing lncRNA-Can-CI, lncRNA-Can-CII, lncRNA-Can-CIII, lncRNA-Non-CI, lncRNA-Non-CII lncRNA-Non-CIII, Intron-Can-CI, Intron-Can-CII, Intron-Can-CIII, Intron-Non-CI, Intron-Non-CI, Intron-Non-CI, TFBS-Can-CI, TFBS-Can-CII, TFBS-Can-CIII, TFBS-Non-CI, TFBS-Non-CII, TFBS-Non-CIII, AS-Can-CI, AS-Can-CII, AS-Can-CIII, AS-Non-CI, AS-Non-CII, AS-Non-CIII, PE-Can-CI, PE-Can-CII, PE-Can-CIII, PE-Non-CI, PE-Non-CII, PE-Non-CIII, CpG-Can-CI, CpG-Can-CII, CpG-Can-CIII, CpG-Non-CI, CpG-Non-CII, and CpG-Non-CIII. (Can indicates canonical HERV; Non indicates non-conical HERV; Cl indicates Gamma-retrovirus/Epsilon-retrovirus-related HERV; ClI indicates Alpha-retrovirus/ Beta-retrovirus-related HERV; ClII indicates Spumavirus-related HERV; LncRNA indicates long non-coding RNA; TFBS indicates transcription factor binding site; AS indicates alternative splice site; PE indicates pseudo exon; CpG indicates CpG Island) HERV-involved lncRNA, intron, and TFBS are found in skin cancer, esophageal cancer, and liver cancer in either canonical HERVs and non-canonical HERVs.</p>
</caption>
<graphic xlink:href="pone.0213770.g007"></graphic>
</fig>
</sec>
</sec>
<sec id="sec023" sec-type="conclusions">
<title>Discussion</title>
<p>In this study, we provide a large-scale and systematic analysis of somatic SNVs in different HERV classes and their subgroups. In our study, we identified four HERV elements with mutation hotspots that overlap with exons of four genes. Those genes are <italic>TNN</italic>, <italic>KIR2DL1</italic>, <italic>ZNF99</italic>, and <italic>OR4K15</italic>. It is well known that LTRs have played a significant role in human gene evolution [<xref ref-type="bibr" rid="pone.0213770.ref076">76</xref>]. Yu et al. have suggested that the mutation hotspot located on the 3’-LTR of HERV-W element may have a regulatory role and might be involved in the activation of neighboring genes and its abnormal expression [<xref ref-type="bibr" rid="pone.0213770.ref030">30</xref>]. A few studies support the involvement of <italic>TNN</italic> and <italic>KIR2DL1</italic> in tumorigenesis. <italic>TNN</italic> is an extracellular matrix protein. It regulates <italic>TGF-beta</italic> to drive breast carcinogenesis and facilitates the migration of cancer cells into bone [<xref ref-type="bibr" rid="pone.0213770.ref077">77</xref>]. KIR2DL1+-HLA-C2+ (human leukocyte antigen) genotype was found in oral cancer patients [<xref ref-type="bibr" rid="pone.0213770.ref078">78</xref>]. In <xref ref-type="fig" rid="pone.0213770.g002">Fig 2</xref>, multiple exons (Exon 1–5) of KIR2DL1, which overlap with MaLR/MST element seems associated with oral cancer. A study indicated that the <italic>ZNF99</italic> gene is involved in the transcription of HERV-W/HERV17/LTR17, which has been implicated in the pathogenesis of multiple sclerosis [<xref ref-type="bibr" rid="pone.0213770.ref079">79</xref>]. Interestingly, the patients with multiple sclerosis have an increased risk of lung, liver, hematologic, and bladder cancer [<xref ref-type="bibr" rid="pone.0213770.ref080">80</xref>]. In <xref ref-type="fig" rid="pone.0213770.g002">Fig 2</xref>, <italic>ZNF99</italic> corresponding to HERV-W/HERV17/LTR17 are found in few cancers; especially, lung cancer. Importantly, patients with the alteration of amino acid position 757 (A to G modification) in <italic>ZNF99</italic> have a lower survival rate than the patients without this variation as shown in <xref ref-type="fig" rid="pone.0213770.g005">Fig 5</xref>. Overall, our data indicated over-representative SNVs (hotspots) strengthen the relationship between these four possible HERV-involved genes and multiple cancer types.</p>
<p>We found the SNVs within the HERV-H/LTR7 element are the major family in Gamma-retrovirus/Epsilon-retrovirus-related (GE) retroviruses—both canonical and non-canonical HERVs (<xref ref-type="fig" rid="pone.0213770.g003">Fig 3</xref>). Liang et al [<xref ref-type="bibr" rid="pone.0213770.ref075">75</xref>] indicates that non-<italic>env</italic>-related transcripts of HERV-H are up-regulated in colon cancer cell lines because of abnormal methylation. A few SNVs in HERV-H/LTR7—both canonical and non-canonical—are associated with colon cancer and provides evidence that HERV-H/LTR7 could be involved in tumorigenesis. Additionally, the HML-2/HERV-K/LTR5 element, which is of Alpha-retrovirus/Beta-retrovirus-related (AB) retroviruses, appears in the blood of patients with breast and lymphoma cancer [<xref ref-type="bibr" rid="pone.0213770.ref081">81</xref>]. Based on the results and relevant research, HERV elements on the non-coding region may play a crucial role in cancer.</p>
<p>SNVs in regulatory DNA elements could broadly affect transcription by altering enhancer and promoter activity or chromatin states, leading to abnormal expression in diseases [<xref ref-type="bibr" rid="pone.0213770.ref082">82</xref>]. Further research supports DNA functional elements such as lncRNAs could be involved in carcinogenesis because mutations are located in the DNA functional region [<xref ref-type="bibr" rid="pone.0213770.ref083">83</xref>, <xref ref-type="bibr" rid="pone.0213770.ref084">84</xref>]. Several SNVs are implicated in the expression of cancer-associated lncRNAs—including <italic>CCAT2</italic> in colorectal cancers [<xref ref-type="bibr" rid="pone.0213770.ref085">85</xref>] and <italic>PCAT-1</italic> in prostate cancer [<xref ref-type="bibr" rid="pone.0213770.ref086">86</xref>]. Additionally, gamma-like retrovirus, one virus of Gamma-retrovirus/Epsilon-retrovirus-related (GE) HERVs, has a connection to carcinogenesis through lncRNA [<xref ref-type="bibr" rid="pone.0213770.ref087">87</xref>]. HERVs that map to lncRNAs which contain multiple somatic SNVs could play a potential role in carcinogenesis, especially, skin and esophageal cancer. Similarly HERVs mapped to introns have been implicated with cancer formation [<xref ref-type="bibr" rid="pone.0213770.ref088">88</xref>]. This was the first report that an intronic mutation was related to the development of cancer [<xref ref-type="bibr" rid="pone.0213770.ref088">88</xref>]. Moreover, copy number variants of the TFBS which is involved in a proliferation effector-gene and an apoptosis effector-gene are highly associated with melanoma and breast cancer [<xref ref-type="bibr" rid="pone.0213770.ref088">88</xref>].</p>
<p>One of the limitations is the lack of comprehensive SNV datasets for protein non-coding regions. Due to the cost of human whole genome sequencing (WGS) in cancer patients, majority of the data is from whole exome sequencing (WEX) instead of WGS. In order to overcome inherent limitations in the data, more functional analysis is required for supporting the potential mechanism of HERV elements’ association with cancers. Another limitation is the mutation calling within repetitive region. To effectively minimize issues that could potentially cause bias in the sequencing result, the review offers insightful perspectives and potential solutions in the alignment step [<xref ref-type="bibr" rid="pone.0213770.ref049">49</xref>]. Firstly, the pipeline of TCGA and other resources that we used adopt similar mate-pair information from reads that were sequenced in pairs for alignment steps to account for repetitive regions in human genome [<xref ref-type="bibr" rid="pone.0213770.ref050">50</xref>]. Duplicate reads are also marked after alignment, sorting and merging via Picard Tools MarkDuplicate function. This is based on the similarity of the 5' and 3' ends of the strands. This is used to protect against a single region being sequenced in much higher quantity than the genome at large; but also help mitigate repetitive regions by essentially labeling them as duplicates and then removing them from consideration. This general same principle also applies to repetitive regions to decrease the chance that all the reads get mapped to one region and variants are called off of that even though the reads are from different very similar regions. Another strategy for handling repeats “is to compute statistics on the depth of coverage for each contig” quoted from Treangen’s paper [<xref ref-type="bibr" rid="pone.0213770.ref049">49</xref>]. The TCGA pipeline checks for higher than 50X sequence coverage for mutation calling (<ext-link ext-link-type="uri" xlink:href="https://docs.gdc.cancer.gov/Data/Introduction/">https://docs.gdc.cancer.gov/Data/Introduction/</ext-link>). TCGA and ICGC data has been used to study regulatory elements including untranslated regions, splice sites and non-coding RNA with repeats [<xref ref-type="bibr" rid="pone.0213770.ref051">51</xref>]. We believe that although there is a possibility that the repeats might result in misalignments, the methods used to determine these SNVs are robust enough to provide reliable mutation calls and calculate SNV hotspots.</p>
<p>This study has identified mutational hotspots in HERVs and attempts to rank HERVs which might be associated with cancer. Although, survival analysis is performed with one mutation, it is clear that there can be other mutations in HERVs which can have a profound impact on cancer progression. The ultimate goal of this study is to provide directions and suggestions for further research related to deciphering the role of HERVs in cancer.</p>
</sec>
<sec id="sec024" sec-type="conclusions">
<title>Conclusion</title>
<p>In this study, we explored the correlation between HERV elements on human protein coding and non-coding regions and multiple cancers based on SNV hotspots. In the HERV element on human protein coding regions, we found four HERV elements that had over-represented nsSNVs and also overlapped with exons of four genes. Additionally, these four HERV elements were associated with at least 14 cancer types—notably skin and lung cancer. We showed that kidney cancer patients with the specific amino acid mutation A757G in ZNF99 within the HERV-W/LTR17/HERV17 element had a lower survival rate based on a survival analysis. We believe that this key mutation could play an important role in kidney cancer.</p>
<p>In the HERV element on human protein non-coding regions, we found 357 canonical and 431 non-canonical HERV elements across different classes which had significantly elevated SNVs counts. All SNVs within these 788 HERV elements overlapped with six DNA functional element groups. HERVs involved in the functional groups lncRNA, introns, and TFBS were shown to be associated with skin, esophageal, and liver cancer. Since we were able to narrow the number of cancer-related SNVs within HERV elements into six groups, we believe these are high-priority experimental targets for studying the molecular mechanisms in cancer progression.</p>
</sec>
<sec id="sec025" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="pone.0213770.s001">
<label>S1 File</label>
<caption>
<p>a~x The distribution of nsSNVs in protein coding region and SNVs in non-coding region by chromosome 1–22, X, Y. X-axis indicates the genomic positions of chromosome. Y-axis indicates the count of mutations. This Manhattan plot represents the distribution of mutations in all positions of the chromosome except for the centromere (empty region).</p>
<p>(DOCX)</p>
</caption>
<media xlink:href="pone.0213770.s001.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0213770.s002">
<label>S1 Fig</label>
<caption>
<p>Each HERV element with count of somatic SNVs within non-coding region. X-axis indicates cancer types. Y-axis indicates Log2Counts (counts mean the number of SNVs). Box plot represents the number of SNVs located in the HERV elements.</p>
<p>(TIFF)</p>
</caption>
<media xlink:href="pone.0213770.s002.tiff">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0213770.s003">
<label>S1 Table</label>
<caption>
<title>HERV elements dataset.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0213770.s003.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0213770.s004">
<label>S2 Table</label>
<caption>
<title>List of 39 canonical and 31 non-canonical HERV clades found in GRCh37/hg19.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0213770.s004.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0213770.s005">
<label>S3 Table</label>
<caption>
<title>The number of SNVs in every 1000 bases and their observed ratio in 22+XY chromosomes.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0213770.s005.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0213770.s006">
<label>S4 Table</label>
<caption>
<title>HERV elements on human protein coding region with significant representation of nsSNVs.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0213770.s006.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0213770.s007">
<label>S5 Table</label>
<caption>
<title>HERV elements on human non-coding region with significant representation of SNVs.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0213770.s007.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0213770.s008">
<label>S6 Table</label>
<caption>
<title>Somatic nsSNVs in HERV elements on human protein coding region.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0213770.s008.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0213770.s009">
<label>S7 Table</label>
<caption>
<title>Somatic SNVs in HERV elements on human non-coding region.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0213770.s009.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0213770.s010">
<label>S8 Table</label>
<caption>
<title>The regions of exon in four genes overlap to HERV elements.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0213770.s010.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0213770.s011">
<label>S9 Table</label>
<caption>
<title>492 nsSNVs in HERV elements on human protein coding region with significant over-representation.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0213770.s011.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0213770.s012">
<label>S10 Table</label>
<caption>
<title>193,439 SNVs in HERV elements on human non-coding region with significant over-representation.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0213770.s012.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0213770.s013">
<label>S11 Table</label>
<caption>
<title>The total count of nsSNVs in functional sites within HERV elements.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0213770.s013.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0213770.s014">
<label>S12 Table</label>
<caption>
<title>SNVs in HERV elements on human non-coding region overlap to DNA functional elements.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0213770.s014.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>The authors would also like to thank Hiral Desai for review and critical feedback.</p>
</ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>HERV</term>
<def>
<p>human endogenous retrovirus</p>
</def>
</def-item>
<def-item>
<term>LTRs</term>
<def>
<p>long terminal repeats</p>
</def>
</def-item>
<def-item>
<term>nsSNV</term>
<def>
<p>non-synonymous single-nucleotide variation</p>
</def>
</def-item>
<def-item>
<term>SNV</term>
<def>
<p>single-nucleotide variation</p>
</def>
</def-item>
<def-item>
<term>TNN</term>
<def>
<p>Tenascin-N</p>
</def>
</def-item>
<def-item>
<term>KIR2DL1</term>
<def>
<p>Killer Cell Immunoglobulin Like Receptor, Two Ig Domains Long Cytoplasmic Tail 1</p>
</def>
</def-item>
<def-item>
<term>OR4K15</term>
<def>
<p>Olfactory Receptor Family 4 Subfamily K Member 15</p>
</def>
</def-item>
<def-item>
<term>ZNF99</term>
<def>
<p>Zinc Finger Protein 99</p>
</def>
</def-item>
<def-item>
<term>PTM</term>
<def>
<p>post translational modification</p>
</def>
</def-item>
<def-item>
<term>lncRNA</term>
<def>
<p>long non-coding RNA</p>
</def>
</def-item>
<def-item>
<term>TFBS</term>
<def>
<p>transcriptional factor binding site</p>
</def>
</def-item>
<def-item>
<term>AS</term>
<def>
<p>alternative splice site</p>
</def>
</def-item>
<def-item>
<term>PE</term>
<def>
<p>pseudo exon</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="pone.0213770.ref001">
<label>1</label>
<mixed-citation publication-type="journal"><name><surname>Bannert</surname><given-names>N</given-names></name>, <name><surname>Kurth</surname><given-names>R</given-names></name>. <article-title>The evolutionary dynamics of human endogenous retroviral families</article-title>. <source/>Annual review of genomics and human genetics. <year>2006</year>;<volume>7</volume>:<fpage>149</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.genom.7.080505.115700</pub-id> .<pub-id pub-id-type="pmid">16722807</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref002">
<label>2</label>
<mixed-citation publication-type="journal"><name><surname>Katzourakis</surname><given-names>A</given-names></name>, <name><surname>Rambaut</surname><given-names>A</given-names></name>, <name><surname>Pybus</surname><given-names>OG</given-names></name>. <article-title>The evolutionary dynamics of endogenous retroviruses</article-title>. <source/>Trends in microbiology. <year>2005</year>;<volume>13</volume>(<issue>10</issue>):<fpage>463</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.tim.2005.08.004</pub-id> .<pub-id pub-id-type="pmid">16109487</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref003">
<label>3</label>
<mixed-citation publication-type="journal"><name><surname>Goff</surname><given-names>SP</given-names></name>. <article-title>Host factors exploited by retroviruses</article-title>. <source/>Nature reviews Microbiology. <year>2007</year>;<volume>5</volume>(<issue>4</issue>):<fpage>253</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro1541</pub-id> .<pub-id pub-id-type="pmid">17325726</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref004">
<label>4</label>
<mixed-citation publication-type="journal"><name><surname>Benachenhou</surname><given-names>F</given-names></name>, <name><surname>Blikstad</surname><given-names>V</given-names></name>, <name><surname>Blomberg</surname><given-names>J</given-names></name>. <article-title>The phylogeny of orthoretroviral long terminal repeats (LTRs).</article-title>
<source/>Gene. <year>2009</year>;<volume>448</volume>(<issue>2</issue>):<fpage>134</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2009.07.002</pub-id> .<pub-id pub-id-type="pmid">19595747</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref005">
<label>5</label>
<mixed-citation publication-type="journal"><name><surname>Stoye</surname><given-names>JP</given-names></name>. <article-title>Studies of endogenous retroviruses reveal a continuing evolutionary saga</article-title>. <source/>Nature reviews Microbiology. <year>2012</year>;<volume>10</volume>(<issue>6</issue>):<fpage>395</fpage>–<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2783</pub-id> .<pub-id pub-id-type="pmid">22565131</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref006">
<label>6</label>
<mixed-citation publication-type="journal"><name><surname>Lander</surname><given-names>ES</given-names></name>, <name><surname>Linton</surname><given-names>LM</given-names></name>, <name><surname>Birren</surname><given-names>B</given-names></name>, <name><surname>Nusbaum</surname><given-names>C</given-names></name>, <name><surname>Zody</surname><given-names>MC</given-names></name>, <name><surname>Baldwin</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Initial sequencing and analysis of the human genome</article-title>. <source/>Nature. <year>2001</year>;<volume>409</volume>(<issue>6822</issue>):<fpage>860</fpage>–<lpage>921</lpage>. <pub-id pub-id-type="doi">10.1038/35057062</pub-id> .<pub-id pub-id-type="pmid">11237011</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref007">
<label>7</label>
<mixed-citation publication-type="book"><name><surname>Wilkinson</surname><given-names>DA MD</given-names></name>, <name><surname>Leong</surname><given-names>JC</given-names></name>. <source/>Endogenous human retroviruses. J L, editor. <publisher-loc>New York</publisher-loc>: <publisher-name>Plenum Press</publisher-name>; <year>1994</year>.</mixed-citation>
</ref>
<ref id="pone.0213770.ref008">
<label>8</label>
<mixed-citation publication-type="journal"><name><surname>Tristem</surname><given-names>M</given-names></name>. <article-title>Identification and characterization of novel human endogenous retrovirus families by phylogenetic screening of the human genome mapping project database</article-title>. <source/>J Virol. <year>2000</year>;<volume>74</volume>(<issue>8</issue>):<fpage>3715</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="pmid">10729147</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref009">
<label>9</label>
<mixed-citation publication-type="journal"><name><surname>Gifford</surname><given-names>RJ</given-names></name>, <name><surname>Blomberg</surname><given-names>J</given-names></name>, <name><surname>Coffin</surname><given-names>JM</given-names></name>, <name><surname>Fan</surname><given-names>H</given-names></name>, <name><surname>Heidmann</surname><given-names>T</given-names></name>, <name><surname>Mayer</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Nomenclature for endogenous retrovirus (ERV) loci</article-title>. <source/>Retrovirology. <year>2018</year>;<volume>15</volume>(<issue>1</issue>):<fpage>59</fpage>
<pub-id pub-id-type="doi">10.1186/s12977-018-0442-1</pub-id>
<pub-id pub-id-type="pmid">30153831</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref010">
<label>10</label>
<mixed-citation publication-type="journal"><name><surname>Andersson</surname><given-names>ML</given-names></name>, <name><surname>Lindeskog</surname><given-names>M</given-names></name>, <name><surname>Medstrand</surname><given-names>P</given-names></name>, <name><surname>Westley</surname><given-names>B</given-names></name>, <name><surname>May</surname><given-names>F</given-names></name>, <name><surname>Blomberg</surname><given-names>J</given-names></name>. <article-title>Diversity of human endogenous retrovirus class II-like sequences</article-title>. <source/>The Journal of general virology. <year>1999</year>;<volume>80</volume> (<issue>Pt 1</issue>):<fpage>255</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1099/0022-1317-80-1-255</pub-id> .<pub-id pub-id-type="pmid">9934709</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref011">
<label>11</label>
<mixed-citation publication-type="journal"><name><surname>Blomberg</surname><given-names>J</given-names></name>, <name><surname>Benachenhou</surname><given-names>F</given-names></name>, <name><surname>Blikstad</surname><given-names>V</given-names></name>, <name><surname>Sperber</surname><given-names>G</given-names></name>, <name><surname>Mayer</surname><given-names>J</given-names></name>. <article-title>Classification and nomenclature of endogenous retroviral sequences (ERVs): problems and recommendations</article-title>. <source/>Gene. <year>2009</year>;<volume>448</volume>(<issue>2</issue>):<fpage>115</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2009.06.007</pub-id> .<pub-id pub-id-type="pmid">19540319</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref012">
<label>12</label>
<mixed-citation publication-type="journal"><name><surname>Mayer</surname><given-names>J</given-names></name>, <name><surname>Blomberg</surname><given-names>J</given-names></name>, <name><surname>Seal</surname><given-names>RL</given-names></name>. <article-title>A revised nomenclature for transcribed human endogenous retroviral loci</article-title>. <source/>Mobile DNA. <year>2011</year>;<volume>2</volume>(<issue>1</issue>):<fpage>7</fpage>
<pub-id pub-id-type="doi">10.1186/1759-8753-2-7</pub-id>
<pub-id pub-id-type="pmid">21542922</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref013">
<label>13</label>
<mixed-citation publication-type="journal"><name><surname>Vargiu</surname><given-names>L</given-names></name>, <name><surname>Rodriguez-Tome</surname><given-names>P</given-names></name>, <name><surname>Sperber</surname><given-names>GO</given-names></name>, <name><surname>Cadeddu</surname><given-names>M</given-names></name>, <name><surname>Grandi</surname><given-names>N</given-names></name>, <name><surname>Blikstad</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Classification and characterization of human endogenous retroviruses; mosaic forms are common</article-title>. <source/>Retrovirology. <year>2016</year>;<volume>13</volume>:<fpage>7</fpage>
<pub-id pub-id-type="doi">10.1186/s12977-015-0232-y</pub-id>
<pub-id pub-id-type="pmid">26800882</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref014">
<label>14</label>
<mixed-citation publication-type="journal"><name><surname>Jurka</surname><given-names>J.</given-names></name>
<article-title>Repbase update: a database and an electronic journal of repetitive elements</article-title>. <source/>Trends in genetics: TIG. <year>2000</year>;<volume>16</volume>(<issue>9</issue>):<fpage>418</fpage>–<lpage>20</lpage>. .<pub-id pub-id-type="pmid">10973072</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref015">
<label>15</label>
<mixed-citation publication-type="journal"><name><surname>Jurka</surname><given-names>J</given-names></name>, <name><surname>Kapitonov</surname><given-names>VV</given-names></name>, <name><surname>Pavlicek</surname><given-names>A</given-names></name>, <name><surname>Klonowski</surname><given-names>P</given-names></name>, <name><surname>Kohany</surname><given-names>O</given-names></name>, <name><surname>Walichiewicz</surname><given-names>J</given-names></name>. <article-title>Repbase Update, a database of eukaryotic repetitive elements</article-title>. <source/>Cytogenetic and genome research. <year>2005</year>;<volume>110</volume>(<issue>1–4</issue>):<fpage>462</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1159/000084979</pub-id> .<pub-id pub-id-type="pmid">16093699</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref016">
<label>16</label>
<mixed-citation publication-type="journal"><name><surname>Sperber</surname><given-names>GO</given-names></name>, <name><surname>Airola</surname><given-names>T</given-names></name>, <name><surname>Jern</surname><given-names>P</given-names></name>, <name><surname>Blomberg</surname><given-names>J</given-names></name>. <article-title>Automated recognition of retroviral sequences in genomic data—RetroTector</article-title>. <source/>Nucleic Acids Res. <year>2007</year>;<volume>35</volume>(<issue>15</issue>):<fpage>4964</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkm515</pub-id>
<pub-id pub-id-type="pmid">17636050</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref017">
<label>17</label>
<mixed-citation publication-type="journal"><name><surname>Elfaitouri</surname><given-names>A</given-names></name>, <name><surname>Shao</surname><given-names>X</given-names></name>, <name><surname>Mattsson Ulfstedt</surname><given-names>J</given-names></name>, <name><surname>Muradrasoli</surname><given-names>S</given-names></name>, <name><surname>Bolin Wiener</surname><given-names>A</given-names></name>, <name><surname>Golbob</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Murine gammaretrovirus group G3 was not found in Swedish patients with myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia</article-title>. <source/>PloS one.
<year>2011</year>;<volume>6</volume>(<issue>10</issue>):<fpage>e24602</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0024602</pub-id>
<pub-id pub-id-type="pmid">22022360</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref018">
<label>18</label>
<mixed-citation publication-type="journal"><name><surname>Jern</surname><given-names>P</given-names></name>, <name><surname>Sperber</surname><given-names>GO</given-names></name>, <name><surname>Blomberg</surname><given-names>J</given-names></name>. <article-title>Use of endogenous retroviral sequences (ERVs) and structural markers for retroviral phylogenetic inference and taxonomy</article-title>. <source/>Retrovirology. <year>2005</year>;<volume>2</volume>:<fpage>50</fpage>
<pub-id pub-id-type="doi">10.1186/1742-4690-2-50</pub-id>
<pub-id pub-id-type="pmid">16092962</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref019">
<label>19</label>
<mixed-citation publication-type="journal"><name><surname>de Parseval</surname><given-names>N</given-names></name>, <name><surname>Lazar</surname><given-names>V</given-names></name>, <name><surname>Casella</surname><given-names>JF</given-names></name>, <name><surname>Benit</surname><given-names>L</given-names></name>, <name><surname>Heidmann</surname><given-names>T</given-names></name>. <article-title>Survey of human genes of retroviral origin: identification and transcriptome of the genes with coding capacity for complete envelope proteins</article-title>. <source/>Journal of virology. <year>2003</year>;<volume>77</volume>(<issue>19</issue>):<fpage>10414</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.77.19.10414-10422.2003</pub-id>
<pub-id pub-id-type="pmid">12970426</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref020">
<label>20</label>
<mixed-citation publication-type="journal"><name><surname>Grow</surname><given-names>EJ</given-names></name>, <name><surname>Flynn</surname><given-names>RA</given-names></name>, <name><surname>Chavez</surname><given-names>SL</given-names></name>, <name><surname>Bayless</surname><given-names>NL</given-names></name>, <name><surname>Wossidlo</surname><given-names>M</given-names></name>, <name><surname>Wesche</surname><given-names>DJ</given-names></name>, <etal>et al</etal>
<article-title>Intrinsic retroviral reactivation in human preimplantation embryos and pluripotent cells</article-title>. <source/>Nature. <year>2015</year>;<volume>522</volume>(<issue>7555</issue>):<fpage>221</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/nature14308</pub-id>
<pub-id pub-id-type="pmid">25896322</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref021">
<label>21</label>
<mixed-citation publication-type="journal"><name><surname>Perron</surname><given-names>H</given-names></name>, <name><surname>Lazarini</surname><given-names>F</given-names></name>, <name><surname>Ruprecht</surname><given-names>K</given-names></name>, <name><surname>Pechoux-Longin</surname><given-names>C</given-names></name>, <name><surname>Seilhean</surname><given-names>D</given-names></name>, <name><surname>Sazdovitch</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Human endogenous retrovirus (HERV)-W ENV and GAG proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions</article-title>. <source/>Journal of neurovirology. <year>2005</year>;<volume>11</volume>(<issue>1</issue>):<fpage>23</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1080/13550280590901741</pub-id> .<pub-id pub-id-type="pmid">15804956</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref022">
<label>22</label>
<mixed-citation publication-type="journal"><name><surname>Galli</surname><given-names>UM</given-names></name>, <name><surname>Sauter</surname><given-names>M</given-names></name>, <name><surname>Lecher</surname><given-names>B</given-names></name>, <name><surname>Maurer</surname><given-names>S</given-names></name>, <name><surname>Herbst</surname><given-names>H</given-names></name>, <name><surname>Roemer</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Human endogenous retrovirus rec interferes with germ cell development in mice and may cause carcinoma in situ, the predecessor lesion of germ cell tumors</article-title>. <source/>Oncogene. <year>2005</year>;<volume>24</volume>(<issue>19</issue>):<fpage>3223</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1208543</pub-id> .<pub-id pub-id-type="pmid">15735668</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref023">
<label>23</label>
<mixed-citation publication-type="journal"><name><surname>Strick</surname><given-names>R</given-names></name>, <name><surname>Ackermann</surname><given-names>S</given-names></name>, <name><surname>Langbein</surname><given-names>M</given-names></name>, <name><surname>Swiatek</surname><given-names>J</given-names></name>, <name><surname>Schubert</surname><given-names>SW</given-names></name>, <name><surname>Hashemolhosseini</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Proliferation and cell-cell fusion of endometrial carcinoma are induced by the human endogenous retroviral Syncytin-1 and regulated by TGF-beta</article-title>. <source/>Journal of molecular medicine. <year>2007</year>;<volume>85</volume>(<issue>1</issue>):<fpage>23</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1007/s00109-006-0104-y</pub-id> .<pub-id pub-id-type="pmid">17066266</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref024">
<label>24</label>
<mixed-citation publication-type="journal"><name><surname>Stauffer</surname><given-names>Y</given-names></name>, <name><surname>Theiler</surname><given-names>G</given-names></name>, <name><surname>Sperisen</surname><given-names>P</given-names></name>, <name><surname>Lebedev</surname><given-names>Y</given-names></name>, <name><surname>Jongeneel</surname><given-names>CV</given-names></name>. <article-title>Digital expression profiles of human endogenous retroviral families in normal and cancerous tissues</article-title>. <source/>Cancer immunity. <year>2004</year>;<volume>4</volume>:<fpage>2</fpage> .<pub-id pub-id-type="pmid">14871062</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref025">
<label>25</label>
<mixed-citation publication-type="journal"><name><surname>Balestrieri</surname><given-names>E</given-names></name>, <name><surname>Arpino</surname><given-names>C</given-names></name>, <name><surname>Matteucci</surname><given-names>C</given-names></name>, <name><surname>Sorrentino</surname><given-names>R</given-names></name>, <name><surname>Pica</surname><given-names>F</given-names></name>, <name><surname>Alessandrelli</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>HERVs expression in Autism Spectrum Disorders.</article-title>
<source/>PloS one. <year>2012</year>;<volume>7</volume>(<issue>11</issue>):<fpage>e48831</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0048831</pub-id>
<pub-id pub-id-type="pmid">23155411</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref026">
<label>26</label>
<mixed-citation publication-type="journal"><name><surname>Armbruester</surname><given-names>V</given-names></name>, <name><surname>Sauter</surname><given-names>M</given-names></name>, <name><surname>Roemer</surname><given-names>K</given-names></name>, <name><surname>Best</surname><given-names>B</given-names></name>, <name><surname>Hahn</surname><given-names>S</given-names></name>, <name><surname>Nty</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Np9 protein of human endogenous retrovirus K interacts with ligand of numb protein X</article-title>. <source/>Journal of virology. <year>2004</year>;<volume>78</volume>(<issue>19</issue>):<fpage>10310</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.78.19.10310-10319.2004</pub-id>
<pub-id pub-id-type="pmid">15367597</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref027">
<label>27</label>
<mixed-citation publication-type="journal"><name><surname>Denne</surname><given-names>M</given-names></name>, <name><surname>Sauter</surname><given-names>M</given-names></name>, <name><surname>Armbruester</surname><given-names>V</given-names></name>, <name><surname>Licht</surname><given-names>JD</given-names></name>, <name><surname>Roemer</surname><given-names>K</given-names></name>, <name><surname>Mueller-Lantzsch</surname><given-names>N</given-names></name>. <article-title>Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein</article-title>. <source/>Journal of virology. <year>2007</year>;<volume>81</volume>(<issue>11</issue>):<fpage>5607</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02771-06</pub-id>
<pub-id pub-id-type="pmid">17360752</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref028">
<label>28</label>
<mixed-citation publication-type="journal"><name><surname>Sin</surname><given-names>HS</given-names></name>, <name><surname>Huh</surname><given-names>JW</given-names></name>, <name><surname>Kim</surname><given-names>DS</given-names></name>, <name><surname>Kang</surname><given-names>DW</given-names></name>, <name><surname>Min</surname><given-names>DS</given-names></name>, <name><surname>Kim</surname><given-names>TH</given-names></name>, <etal>et al</etal>
<article-title>Transcriptional control of the HERV-H LTR element of the GSDML gene in human tissues and cancer cells</article-title>. <source/>Archives of virology. <year>2006</year>;<volume>151</volume>(<issue>10</issue>):<fpage>1985</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-006-0764-5</pub-id> .<pub-id pub-id-type="pmid">16625320</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref029">
<label>29</label>
<mixed-citation publication-type="journal"><name><surname>Romanish</surname><given-names>MT</given-names></name>, <name><surname>Lock</surname><given-names>WM</given-names></name>, <name><surname>van de Lagemaat</surname><given-names>LN</given-names></name>, <name><surname>Dunn</surname><given-names>CA</given-names></name>, <name><surname>Mager</surname><given-names>DL</given-names></name>. <article-title>Repeated recruitment of LTR retrotransposons as promoters by the anti-apoptotic locus NAIP during mammalian evolution</article-title>. <source/>PLoS genetics. <year>2007</year>;<volume>3</volume>(<issue>1</issue>):<fpage>e10</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.0030010</pub-id>
<pub-id pub-id-type="pmid">17222062</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref030">
<label>30</label>
<mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>H</given-names></name>, <name><surname>Liu</surname><given-names>T</given-names></name>, <name><surname>Zhao</surname><given-names>Z</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Zeng</surname><given-names>J</given-names></name>, <name><surname>Liu</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Mutations in 3'-long terminal repeat of HERV-W family in chromosome 7 upregulate syncytin-1 expression in urothelial cell carcinoma of the bladder through interacting with c-Myb</article-title>. <source/>Oncogene. <year>2014</year>;<volume>33</volume>(<issue>30</issue>):<fpage>3947</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2013.366</pub-id> .<pub-id pub-id-type="pmid">24013223</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref031">
<label>31</label>
<mixed-citation publication-type="journal"><name><surname>Glinsky</surname><given-names>GV</given-names></name>. <article-title>Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors</article-title>. <source/>Cancer letters. <year>2016</year>;<volume>381</volume>(<issue>1</issue>):<fpage>176</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2016.08.001</pub-id> .<pub-id pub-id-type="pmid">27497790</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref032">
<label>32</label>
<mixed-citation publication-type="journal"><name><surname>Kuntzer</surname><given-names>J</given-names></name>, <name><surname>Eggle</surname><given-names>D</given-names></name>, <name><surname>Klostermann</surname><given-names>S</given-names></name>, <name><surname>Burtscher</surname><given-names>H</given-names></name>. <article-title>Human variation databases</article-title>. <source/>Database: the journal of biological databases and curation. <year>2010</year>;2010:<fpage>baq015</fpage>
<pub-id pub-id-type="doi">10.1093/database/baq015</pub-id>
<pub-id pub-id-type="pmid">20639550</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref033">
<label>33</label>
<mixed-citation publication-type="journal"><name><surname>Genomes Project</surname><given-names>C</given-names></name>, <name><surname>Abecasis</surname><given-names>GR</given-names></name>, <name><surname>Auton</surname><given-names>A</given-names></name>, <name><surname>Brooks</surname><given-names>LD</given-names></name>, <name><surname>DePristo</surname><given-names>MA</given-names></name>, <name><surname>Durbin</surname><given-names>RM</given-names></name>, <etal>et al</etal>
<article-title>An integrated map of genetic variation from 1,092 human genomes</article-title>. <source/>Nature. <year>2012</year>;<volume>491</volume>(<issue>7422</issue>):<fpage>56</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1038/nature11632</pub-id>
<pub-id pub-id-type="pmid">23128226</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref034">
<label>34</label>
<mixed-citation publication-type="journal"><name><surname>Lehrach</surname><given-names>H.</given-names></name>
<article-title>DNA sequencing methods in human genetics and disease research</article-title>. <source/>F1000prime reports. <year>2013</year>;<volume>5</volume>:<fpage>34</fpage>
<pub-id pub-id-type="doi">10.12703/P5-34</pub-id>
<pub-id pub-id-type="pmid">24049638</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref035">
<label>35</label>
<mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>TJ</given-names></name>, <name><surname>Shamsaddini</surname><given-names>A</given-names></name>, <name><surname>Pan</surname><given-names>Y</given-names></name>, <name><surname>Smith</surname><given-names>K</given-names></name>, <name><surname>Crichton</surname><given-names>DJ</given-names></name>, <name><surname>Simonyan</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>A framework for organizing cancer-related variations from existing databases, publications and NGS data using a High-performance Integrated Virtual Environment (HIVE)</article-title>. <source/>Database (Oxford).
<year>2014</year>;2014:<fpage>bau022</fpage>
<pub-id pub-id-type="doi">10.1093/database/bau022</pub-id>
<pub-id pub-id-type="pmid">24667251</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref036">
<label>36</label>
<mixed-citation publication-type="journal"><name><surname>Kandoth</surname><given-names>C</given-names></name>, <name><surname>McLellan</surname><given-names>MD</given-names></name>, <name><surname>Vandin</surname><given-names>F</given-names></name>, <name><surname>Ye</surname><given-names>K</given-names></name>, <name><surname>Niu</surname><given-names>B</given-names></name>, <name><surname>Lu</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Mutational landscape and significance across 12 major cancer types</article-title>. <source/>Nature. <year>2013</year>;<volume>502</volume>(<issue>7471</issue>):<fpage>333</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nature12634</pub-id>
<pub-id pub-id-type="pmid">24132290</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref037">
<label>37</label>
<mixed-citation publication-type="journal"><name><surname>Reimand</surname><given-names>J</given-names></name>, <name><surname>Wagih</surname><given-names>O</given-names></name>, <name><surname>Bader</surname><given-names>GD</given-names></name>. <article-title>The mutational landscape of phosphorylation signaling in cancer</article-title>. <source/>Sci Rep. <year>2013</year>;<volume>3</volume>:<fpage>2651</fpage>
<pub-id pub-id-type="doi">10.1038/srep02651</pub-id>
<pub-id pub-id-type="pmid">24089029</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref038">
<label>38</label>
<mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>ML</given-names></name>, <name><surname>Reznik</surname><given-names>E</given-names></name>, <name><surname>Gauthier</surname><given-names>NP</given-names></name>, <name><surname>Aksoy</surname><given-names>BA</given-names></name>, <name><surname>Korkut</surname><given-names>A</given-names></name>, <name><surname>Gao</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Pan-Cancer Analysis of Mutation Hotspots in Protein Domains</article-title>. <source/>Cell Syst. <year>2015</year>;<volume>1</volume>(<issue>3</issue>):<fpage>197</fpage>–<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1016/j.cels.2015.08.014</pub-id>
<pub-id pub-id-type="pmid">27135912</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref039">
<label>39</label>
<mixed-citation publication-type="journal"><name><surname>Dingerdissen</surname><given-names>HM</given-names></name>, <name><surname>Torcivia-Rodriguez</surname><given-names>J</given-names></name>, <name><surname>Hu</surname><given-names>Y</given-names></name>, <name><surname>Chang</surname><given-names>TC</given-names></name>, <name><surname>Mazumder</surname><given-names>R</given-names></name>, <name><surname>Kahsay</surname><given-names>R</given-names></name>. <article-title>BioMuta and BioXpress: mutation and expression knowledgebases for cancer biomarker discovery</article-title>. <source/>Nucleic acids research. <year>2018</year>;<volume>46</volume>(<issue>D1</issue>):<fpage>D1128</fpage>–<lpage>D36</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx907</pub-id>
<pub-id pub-id-type="pmid">30053270</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref040">
<label>40</label>
<mixed-citation publication-type="journal"><collab>Cancer Genome Atlas Research N</collab>, <name><surname>Weinstein</surname><given-names>JN</given-names></name>, <name><surname>Collisson</surname><given-names>EA</given-names></name>, <name><surname>Mills</surname><given-names>GB</given-names></name>, <name><surname>Shaw</surname><given-names>KR</given-names></name>, <name><surname>Ozenberger</surname><given-names>BA</given-names></name>, <etal>et al</etal>
<article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title>. <source/>Nature genetics. <year>2013</year>;<volume>45</volume>(<issue>10</issue>):<fpage>1113</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2764</pub-id>
<pub-id pub-id-type="pmid">24071849</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref041">
<label>41</label>
<mixed-citation publication-type="journal"><name><surname>Landrum</surname><given-names>MJ</given-names></name>, <name><surname>Lee</surname><given-names>JM</given-names></name>, <name><surname>Riley</surname><given-names>GR</given-names></name>, <name><surname>Jang</surname><given-names>W</given-names></name>, <name><surname>Rubinstein</surname><given-names>WS</given-names></name>, <name><surname>Church</surname><given-names>DM</given-names></name>, <etal>et al</etal>
<article-title>ClinVar: public archive of relationships among sequence variation and human phenotype</article-title>. <source/>Nucleic acids research. <year>2014</year>;<volume>42</volume>(Database issue):<fpage>D980</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1113</pub-id>
<pub-id pub-id-type="pmid">24234437</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref042">
<label>42</label>
<mixed-citation publication-type="journal"><name><surname>Forbes</surname><given-names>SA</given-names></name>, <name><surname>Beare</surname><given-names>D</given-names></name>, <name><surname>Gunasekaran</surname><given-names>P</given-names></name>, <name><surname>Leung</surname><given-names>K</given-names></name>, <name><surname>Bindal</surname><given-names>N</given-names></name>, <name><surname>Boutselakis</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>COSMIC: exploring the world's knowledge of somatic mutations in human cancer</article-title>. <source/>Nucleic acids research. <year>2015</year>;<volume>43</volume>(Database issue):<fpage>D805</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku1075</pub-id>
<pub-id pub-id-type="pmid">25355519</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref043">
<label>43</label>
<mixed-citation publication-type="journal"><name><surname>International Cancer Genome</surname><given-names>C</given-names></name>, <name><surname>Hudson</surname><given-names>TJ</given-names></name>, <name><surname>Anderson</surname><given-names>W</given-names></name>, <name><surname>Artez</surname><given-names>A</given-names></name>, <name><surname>Barker</surname><given-names>AD</given-names></name>, <name><surname>Bell</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>International network of cancer genome projects</article-title>. <source/>Nature. <year>2010</year>;<volume>464</volume>(<issue>7291</issue>):<fpage>993</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nature08987</pub-id>
<pub-id pub-id-type="pmid">20393554</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref044">
<label>44</label>
<mixed-citation publication-type="journal"><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name>, <name><surname>Perez-Llamas</surname><given-names>C</given-names></name>, <name><surname>Deu-Pons</surname><given-names>J</given-names></name>, <name><surname>Tamborero</surname><given-names>D</given-names></name>, <name><surname>Schroeder</surname><given-names>MP</given-names></name>, <name><surname>Jene-Sanz</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>IntOGen-mutations identifies cancer drivers across tumor types</article-title>. <source/>Nature methods. <year>2013</year>;<volume>10</volume>(<issue>11</issue>):<fpage>1081</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2642</pub-id> .<pub-id pub-id-type="pmid">24037244</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref045">
<label>45</label>
<mixed-citation publication-type="journal"><name><surname>Boutet</surname><given-names>E</given-names></name>, <name><surname>Lieberherr</surname><given-names>D</given-names></name>, <name><surname>Tognolli</surname><given-names>M</given-names></name>, <name><surname>Schneider</surname><given-names>M</given-names></name>, <name><surname>Bansal</surname><given-names>P</given-names></name>, <name><surname>Bridge</surname><given-names>AJ</given-names></name>, <etal>et al</etal>
<article-title>UniProtKB/Swiss-Prot, the Manually Annotated Section of the UniProt KnowledgeBase: How to Use the Entry View.</article-title>
<source/>Methods in molecular biology. <year>2016</year>;<volume>1374</volume>:<fpage>23</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-3167-5_2</pub-id> .<pub-id pub-id-type="pmid">26519399</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref046">
<label>46</label>
<mixed-citation publication-type="journal"><name><surname>Cibulskis</surname><given-names>K</given-names></name>, <name><surname>Lawrence</surname><given-names>MS</given-names></name>, <name><surname>Carter</surname><given-names>SL</given-names></name>, <name><surname>Sivachenko</surname><given-names>A</given-names></name>, <name><surname>Jaffe</surname><given-names>D</given-names></name>, <name><surname>Sougnez</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</article-title>. <source/>Nature biotechnology. <year>2013</year>;<volume>31</volume>(<issue>3</issue>):<fpage>213</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2514</pub-id>
<pub-id pub-id-type="pmid">23396013</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref047">
<label>47</label>
<mixed-citation publication-type="journal"><name><surname>Saunders</surname><given-names>CT</given-names></name>, <name><surname>Wong</surname><given-names>WS</given-names></name>, <name><surname>Swamy</surname><given-names>S</given-names></name>, <name><surname>Becq</surname><given-names>J</given-names></name>, <name><surname>Murray</surname><given-names>LJ</given-names></name>, <name><surname>Cheetham</surname><given-names>RK</given-names></name>. <article-title>Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs</article-title>. <source/>Bioinformatics. <year>2012</year>;<volume>28</volume>(<issue>14</issue>):<fpage>1811</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bts271</pub-id> .<pub-id pub-id-type="pmid">22581179</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref048">
<label>48</label>
<mixed-citation publication-type="journal"><name><surname>Alioto</surname><given-names>TS</given-names></name>, <name><surname>Buchhalter</surname><given-names>I</given-names></name>, <name><surname>Derdak</surname><given-names>S</given-names></name>, <name><surname>Hutter</surname><given-names>B</given-names></name>, <name><surname>Eldridge</surname><given-names>MD</given-names></name>, <name><surname>Hovig</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing</article-title>. <source/>Nature communications. <year>2015</year>;<volume>6</volume>:<fpage>10001</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms10001</pub-id>
<pub-id pub-id-type="pmid">26647970</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref049">
<label>49</label>
<mixed-citation publication-type="journal"><name><surname>Treangen</surname><given-names>TJ</given-names></name>, <name><surname>Salzberg</surname><given-names>SL</given-names></name>. <article-title>Repetitive DNA and next-generation sequencing: computational challenges and solutions</article-title>. <source/>Nature reviews Genetics. <year>2011</year>;<volume>13</volume>(<issue>1</issue>):<fpage>36</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1038/nrg3117</pub-id>
<pub-id pub-id-type="pmid">22124482</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref050">
<label>50</label>
<mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Durbin</surname><given-names>R</given-names></name>. <article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title>. <source/>Bioinformatics. <year>2009</year>;<volume>25</volume>(<issue>14</issue>):<fpage>1754</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp324</pub-id>
<pub-id pub-id-type="pmid">19451168</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref051">
<label>51</label>
<mixed-citation publication-type="journal"><name><surname>Diederichs</surname><given-names>S</given-names></name>, <name><surname>Bartsch</surname><given-names>L</given-names></name>, <name><surname>Berkmann</surname><given-names>JC</given-names></name>, <name><surname>Frose</surname><given-names>K</given-names></name>, <name><surname>Heitmann</surname><given-names>J</given-names></name>, <name><surname>Hoppe</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations</article-title>. <source/>EMBO molecular medicine. <year>2016</year>;<volume>8</volume>(<issue>5</issue>):<fpage>442</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.15252/emmm.201506055</pub-id>
<pub-id pub-id-type="pmid">26992833</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref052">
<label>52</label>
<mixed-citation publication-type="journal"><name><surname>Chan</surname><given-names>PP</given-names></name>, <name><surname>Lowe</surname><given-names>TM</given-names></name>. <article-title>GtRNAdb: a database of transfer RNA genes detected in genomic sequence</article-title>. <source/>Nucleic acids research. <year>2009</year>;<volume>37</volume>(Database issue):<fpage>D93</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkn787</pub-id>
<pub-id pub-id-type="pmid">18984615</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref053">
<label>53</label>
<mixed-citation publication-type="journal"><name><surname>Eddy</surname><given-names>SR</given-names></name>, <name><surname>Durbin</surname><given-names>R</given-names></name>. <article-title>RNA sequence analysis using covariance models</article-title>. <source/>Nucleic acids research. <year>1994</year>;<volume>22</volume>(<issue>11</issue>):<fpage>2079</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="pmid">8029015</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref054">
<label>54</label>
<mixed-citation publication-type="journal"><name><surname>Lowe</surname><given-names>TM</given-names></name>, <name><surname>Eddy</surname><given-names>SR</given-names></name>. <article-title>tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence</article-title>. <source/>Nucleic acids research. <year>1997</year>;<volume>25</volume>(<issue>5</issue>):<fpage>955</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="pmid">9023104</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref055">
<label>55</label>
<mixed-citation publication-type="journal"><name><surname>Griffith</surname><given-names>OL</given-names></name>, <name><surname>Montgomery</surname><given-names>SB</given-names></name>, <name><surname>Bernier</surname><given-names>B</given-names></name>, <name><surname>Chu</surname><given-names>B</given-names></name>, <name><surname>Kasaian</surname><given-names>K</given-names></name>, <name><surname>Aerts</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>ORegAnno: an open-access community-driven resource for regulatory annotation</article-title>. <source/>Nucleic acids research. <year>2008</year>;<volume>36</volume>(Database issue):<fpage>D107</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkm967</pub-id>
<pub-id pub-id-type="pmid">18006570</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref056">
<label>56</label>
<mixed-citation publication-type="journal"><name><surname>Montgomery</surname><given-names>SB</given-names></name>, <name><surname>Griffith</surname><given-names>OL</given-names></name>, <name><surname>Sleumer</surname><given-names>MC</given-names></name>, <name><surname>Bergman</surname><given-names>CM</given-names></name>, <name><surname>Bilenky</surname><given-names>M</given-names></name>, <name><surname>Pleasance</surname><given-names>ED</given-names></name>, <etal>et al</etal>
<article-title>ORegAnno: an open access database and curation system for literature-derived promoters, transcription factor binding sites and regulatory variation</article-title>. <source/>Bioinformatics. <year>2006</year>;<volume>22</volume>(<issue>5</issue>):<fpage>637</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btk027</pub-id> .<pub-id pub-id-type="pmid">16397004</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref057">
<label>57</label>
<mixed-citation publication-type="journal"><name><surname>Griffiths-Jones</surname><given-names>S</given-names></name>, <name><surname>Grocock</surname><given-names>RJ</given-names></name>, <name><surname>van Dongen</surname><given-names>S</given-names></name>, <name><surname>Bateman</surname><given-names>A</given-names></name>, <name><surname>Enright</surname><given-names>AJ</given-names></name>. <article-title>miRBase: microRNA sequences, targets and gene nomenclature</article-title>. <source/>Nucleic acids research. <year>2006</year>;<volume>34</volume>(Database issue):<fpage>D140</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkj112</pub-id>
<pub-id pub-id-type="pmid">16381832</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref058">
<label>58</label>
<mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Harrison</surname><given-names>PM</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Gerstein</surname><given-names>M</given-names></name>. <article-title>Millions of years of evolution preserved: a comprehensive catalog of the processed pseudogenes in the human genome</article-title>. <source/>Genome research. <year>2003</year>;<volume>13</volume>(<issue>12</issue>):<fpage>2541</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1101/gr.1429003</pub-id>
<pub-id pub-id-type="pmid">14656962</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref059">
<label>59</label>
<mixed-citation publication-type="journal"><name><surname>Zheng</surname><given-names>D</given-names></name>, <name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Harrison</surname><given-names>PM</given-names></name>, <name><surname>Karro</surname><given-names>J</given-names></name>, <name><surname>Carriero</surname><given-names>N</given-names></name>, <name><surname>Gerstein</surname><given-names>M</given-names></name>. <article-title>Integrated pseudogene annotation for human chromosome 22: evidence for transcription</article-title>. <source/>Journal of molecular biology. <year>2005</year>;<volume>349</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2005.02.072</pub-id> .<pub-id pub-id-type="pmid">15876366</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref060">
<label>60</label>
<mixed-citation publication-type="journal"><name><surname>Pennacchio</surname><given-names>LA</given-names></name>, <name><surname>Ahituv</surname><given-names>N</given-names></name>, <name><surname>Moses</surname><given-names>AM</given-names></name>, <name><surname>Prabhakar</surname><given-names>S</given-names></name>, <name><surname>Nobrega</surname><given-names>MA</given-names></name>, <name><surname>Shoukry</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>In vivo enhancer analysis of human conserved non-coding sequences</article-title>. <source/>Nature. <year>2006</year>;<volume>444</volume>(<issue>7118</issue>):<fpage>499</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1038/nature05295</pub-id> .<pub-id pub-id-type="pmid">17086198</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref061">
<label>61</label>
<mixed-citation publication-type="journal"><name><surname>Lestrade</surname><given-names>L</given-names></name>, <name><surname>Weber</surname><given-names>MJ</given-names></name>. <article-title>snoRNA-LBME-db, a comprehensive database of human H/ACA and C/D box snoRNAs</article-title>. <source/>Nucleic acids research. <year>2006</year>;<volume>34</volume>(Database issue):<fpage>D158</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkj002</pub-id>
<pub-id pub-id-type="pmid">16381836</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref062">
<label>62</label>
<mixed-citation publication-type="journal"><name><surname>Gerstein</surname><given-names>MB</given-names></name>, <name><surname>Kundaje</surname><given-names>A</given-names></name>, <name><surname>Hariharan</surname><given-names>M</given-names></name>, <name><surname>Landt</surname><given-names>SG</given-names></name>, <name><surname>Yan</surname><given-names>KK</given-names></name>, <name><surname>Cheng</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Architecture of the human regulatory network derived from ENCODE data</article-title>. <source/>Nature. <year>2012</year>;<volume>489</volume>(<issue>7414</issue>):<fpage>91</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1038/nature11245</pub-id>
<pub-id pub-id-type="pmid">22955619</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref063">
<label>63</label>
<mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Zhuang</surname><given-names>J</given-names></name>, <name><surname>Iyer</surname><given-names>S</given-names></name>, <name><surname>Lin</surname><given-names>XY</given-names></name>, <name><surname>Greven</surname><given-names>MC</given-names></name>, <name><surname>Kim</surname><given-names>BH</given-names></name>, <etal>et al</etal>
<article-title>Factorbook.org: a Wiki-based database for transcription factor-binding data generated by the ENCODE consortium</article-title>. <source/>Nucleic acids research. <year>2013</year>;<volume>41</volume>(Database issue):<fpage>D171</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gks1221</pub-id>
<pub-id pub-id-type="pmid">23203885</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref064">
<label>64</label>
<mixed-citation publication-type="journal"><name><surname>Volders</surname><given-names>PJ</given-names></name>, <name><surname>Verheggen</surname><given-names>K</given-names></name>, <name><surname>Menschaert</surname><given-names>G</given-names></name>, <name><surname>Vandepoele</surname><given-names>K</given-names></name>, <name><surname>Martens</surname><given-names>L</given-names></name>, <name><surname>Vandesompele</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>An update on LNCipedia: a database for annotated human lncRNA sequences</article-title>. <source/>Nucleic acids research. <year>2015</year>;<volume>43</volume>(Database issue):<fpage>D174</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku1060</pub-id>
<pub-id pub-id-type="pmid">25378313</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref065">
<label>65</label>
<mixed-citation publication-type="journal"><name><surname>Karagiannis</surname><given-names>K</given-names></name>, <name><surname>Simonyan</surname><given-names>V</given-names></name>, <name><surname>Mazumder</surname><given-names>R</given-names></name>. <article-title>SNVDis: a proteome-wide analysis service for evaluating nsSNVs in protein functional sites and pathways</article-title>. <source/>Genomics, proteomics &amp; bioinformatics. <year>2013</year>;<volume>11</volume>(<issue>2</issue>):<fpage>122</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.gpb.2012.10.003</pub-id>
<pub-id pub-id-type="pmid">23618375</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref066">
<label>66</label>
<mixed-citation publication-type="journal"><name><surname>McElroy</surname><given-names>K</given-names></name>, <name><surname>Zagordi</surname><given-names>O</given-names></name>, <name><surname>Bull</surname><given-names>R</given-names></name>, <name><surname>Luciani</surname><given-names>F</given-names></name>, <name><surname>Beerenwinkel</surname><given-names>N</given-names></name>. <article-title>Accurate single nucleotide variant detection in viral populations by combining probabilistic clustering with a statistical test of strand bias</article-title>. <source/>BMC genomics. <year>2013</year>;<volume>14</volume>:<fpage>501</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2164-14-501</pub-id>
<pub-id pub-id-type="pmid">23879730</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref067">
<label>67</label>
<mixed-citation publication-type="journal"><name><surname>Mi</surname><given-names>H</given-names></name>, <name><surname>Thomas</surname><given-names>P</given-names></name>. <article-title>PANTHER pathway: an ontology-based pathway database coupled with data analysis tools.</article-title>
<source/>Methods in molecular biology. <year>2009</year>;<volume>563</volume>:<fpage>123</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-60761-175-2_7</pub-id> .<pub-id pub-id-type="pmid">19597783</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref068">
<label>68</label>
<mixed-citation publication-type="journal"><name><surname>Pan</surname><given-names>Y</given-names></name>, <name><surname>Karagiannis</surname><given-names>K</given-names></name>, <name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>Dingerdissen</surname><given-names>H</given-names></name>, <name><surname>Shamsaddini</surname><given-names>A</given-names></name>, <name><surname>Wan</surname><given-names>Q</given-names></name>, <etal>et al</etal>
<article-title>Human germline and pan-cancer variomes and their distinct functional profiles</article-title>. <source/>Nucleic acids research. <year>2014</year>;<volume>42</volume>(<issue>18</issue>):<fpage>11570</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku772</pub-id>
<pub-id pub-id-type="pmid">25232094</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref069">
<label>69</label>
<mixed-citation publication-type="journal"><name><surname>Gustedt</surname><given-names>J.</given-names></name>
<article-title>Efficient sampling of random permutations</article-title>. <source/>Journal of Discrete Algorithms. <year>2008</year>;<volume>6</volume>. Epub 139.</mixed-citation>
</ref>
<ref id="pone.0213770.ref070">
<label>70</label>
<mixed-citation publication-type="journal"><name><surname>Wan</surname><given-names>Q</given-names></name>, <name><surname>Dingerdissen</surname><given-names>H</given-names></name>, <name><surname>Fan</surname><given-names>Y</given-names></name>, <name><surname>Gulzar</surname><given-names>N</given-names></name>, <name><surname>Pan</surname><given-names>Y</given-names></name>, <name><surname>Wu</surname><given-names>TJ</given-names></name>, <etal>et al</etal>
<article-title>BioXpress: an integrated RNA-seq-derived gene expression database for pan-cancer analysis.</article-title>
<source/>Database: the journal of biological databases and curation. <year>2015</year>;2015. <pub-id pub-id-type="doi">10.1093/database/bav019</pub-id>
<pub-id pub-id-type="pmid">25819073</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref071">
<label>71</label>
<mixed-citation publication-type="journal"><name><surname>Love</surname><given-names>MI</given-names></name>, <name><surname>Huber</surname><given-names>W</given-names></name>, <name><surname>Anders</surname><given-names>S</given-names></name>. <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source/>Genome biology. <year>2014</year>;<volume>15</volume>(<issue>12</issue>):<fpage>550</fpage>
<pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id>
<pub-id pub-id-type="pmid">25516281</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref072">
<label>72</label>
<mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>TJ</given-names></name>, <name><surname>Schriml</surname><given-names>LM</given-names></name>, <name><surname>Chen</surname><given-names>QR</given-names></name>, <name><surname>Colbert</surname><given-names>M</given-names></name>, <name><surname>Crichton</surname><given-names>DJ</given-names></name>, <name><surname>Finney</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Generating a focused view of disease ontology cancer terms for pan-cancer data integration and analysis</article-title>. <source/>Database: the journal of biological databases and curation. <year>2015</year>;2015:<fpage>bav032</fpage>
<pub-id pub-id-type="doi">10.1093/database/bav032</pub-id>
<pub-id pub-id-type="pmid">25841438</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref073">
<label>73</label>
<mixed-citation publication-type="journal"><name><surname>George</surname><given-names>B</given-names></name>, <name><surname>Seals</surname><given-names>S</given-names></name>, <name><surname>Aban</surname><given-names>I</given-names></name>. <article-title>Survival analysis and regression models</article-title>. <source/>Journal of nuclear cardiology: official publication of the American Society of Nuclear Cardiology. <year>2014</year>;<volume>21</volume>(<issue>4</issue>):<fpage>686</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1007/s12350-014-9908-2</pub-id>
<pub-id pub-id-type="pmid">24810431</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref074">
<label>74</label>
<mixed-citation publication-type="journal"><name><surname>Gibb</surname><given-names>EA</given-names></name>, <name><surname>Warren</surname><given-names>RL</given-names></name>, <name><surname>Wilson</surname><given-names>GW</given-names></name>, <name><surname>Brown</surname><given-names>SD</given-names></name>, <name><surname>Robertson</surname><given-names>GA</given-names></name>, <name><surname>Morin</surname><given-names>GB</given-names></name>, <etal>et al</etal>
<article-title>Activation of an endogenous retrovirus-associated long non-coding RNA in human adenocarcinoma</article-title>. <source/>Genome medicine. <year>2015</year>;<volume>7</volume>(<issue>1</issue>):<fpage>22</fpage>
<pub-id pub-id-type="doi">10.1186/s13073-015-0142-6</pub-id>
<pub-id pub-id-type="pmid">25821520</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref075">
<label>75</label>
<mixed-citation publication-type="journal"><name><surname>Liang</surname><given-names>Q</given-names></name>, <name><surname>Xu</surname><given-names>Z</given-names></name>, <name><surname>Xu</surname><given-names>R</given-names></name>, <name><surname>Wu</surname><given-names>L</given-names></name>, <name><surname>Zheng</surname><given-names>S</given-names></name>. <article-title>Expression patterns of non-coding spliced transcripts from human endogenous retrovirus HERV-H elements in colon cancer</article-title>. <source/>PloS one. <year>2012</year>;<volume>7</volume>(<issue>1</issue>):<fpage>e29950</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0029950</pub-id>
<pub-id pub-id-type="pmid">22238681</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref076">
<label>76</label>
<mixed-citation publication-type="journal"><name><surname>Piriyapongsa</surname><given-names>J</given-names></name>, <name><surname>Polavarapu</surname><given-names>N</given-names></name>, <name><surname>Borodovsky</surname><given-names>M</given-names></name>, <name><surname>McDonald</surname><given-names>J</given-names></name>. <article-title>Exonization of the LTR transposable elements in human genome</article-title>. <source/>BMC genomics. <year>2007</year>;<volume>8</volume>:<fpage>291</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2164-8-291</pub-id>
<pub-id pub-id-type="pmid">17725822</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref077">
<label>77</label>
<mixed-citation publication-type="journal"><name><surname>Chiovaro</surname><given-names>F</given-names></name>, <name><surname>Martina</surname><given-names>E</given-names></name>, <name><surname>Bottos</surname><given-names>A</given-names></name>, <name><surname>Scherberich</surname><given-names>A</given-names></name>, <name><surname>Hynes</surname><given-names>NE</given-names></name>, <name><surname>Chiquet-Ehrismann</surname><given-names>R</given-names></name>. <article-title>Transcriptional regulation of tenascin-W by TGF-beta signaling in the bone metastatic niche of breast cancer cells</article-title>. <source/>International journal of cancer. <year>2015</year>;<volume>137</volume>(<issue>8</issue>):<fpage>1842</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.29565</pub-id>
<pub-id pub-id-type="pmid">25868708</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref078">
<label>78</label>
<mixed-citation publication-type="journal"><name><surname>Dutta</surname><given-names>A</given-names></name>, <name><surname>Saikia</surname><given-names>N</given-names></name>, <name><surname>Phookan</surname><given-names>J</given-names></name>, <name><surname>Baruah</surname><given-names>MN</given-names></name>, <name><surname>Baruah</surname><given-names>S</given-names></name>. <article-title>Association of killer cell immunoglobulin-like receptor gene 2DL1 and its HLA-C2 ligand with family history of cancer in oral squamous cell carcinoma</article-title>. <source/>Immunogenetics. <year>2014</year>;<volume>66</volume>(<issue>7–8</issue>):<fpage>439</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1007/s00251-014-0778-1</pub-id> .<pub-id pub-id-type="pmid">24818561</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref079">
<label>79</label>
<mixed-citation publication-type="journal"><name><surname>Schmitt</surname><given-names>K</given-names></name>, <name><surname>Richter</surname><given-names>C</given-names></name>, <name><surname>Backes</surname><given-names>C</given-names></name>, <name><surname>Meese</surname><given-names>E</given-names></name>, <name><surname>Ruprecht</surname><given-names>K</given-names></name>, <name><surname>Mayer</surname><given-names>J</given-names></name>. <article-title>Comprehensive analysis of human endogenous retrovirus group HERV-W locus transcription in multiple sclerosis brain lesions by high-throughput amplicon sequencing</article-title>. <source/>Journal of virology. <year>2013</year>;<volume>87</volume>(<issue>24</issue>):<fpage>13837</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02388-13</pub-id>
<pub-id pub-id-type="pmid">24109235</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref080">
<label>80</label>
<mixed-citation publication-type="journal"><name><surname>Onishi</surname><given-names>A</given-names></name>, <name><surname>Sugiyama</surname><given-names>D</given-names></name>, <name><surname>Kumagai</surname><given-names>S</given-names></name>, <name><surname>Morinobu</surname><given-names>A</given-names></name>. <article-title>Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies</article-title>. <source/>Arthritis and rheumatism. <year>2013</year>;<volume>65</volume>(<issue>7</issue>):<fpage>1913</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1002/art.37969</pub-id> .<pub-id pub-id-type="pmid">23576072</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref081">
<label>81</label>
<mixed-citation publication-type="journal"><name><surname>Contreras-Galindo</surname><given-names>R</given-names></name>, <name><surname>Kaplan</surname><given-names>MH</given-names></name>, <name><surname>Leissner</surname><given-names>P</given-names></name>, <name><surname>Verjat</surname><given-names>T</given-names></name>, <name><surname>Ferlenghi</surname><given-names>I</given-names></name>, <name><surname>Bagnoli</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer</article-title>. <source/>Journal of virology. <year>2008</year>;<volume>82</volume>(<issue>19</issue>):<fpage>9329</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00646-08</pub-id>
<pub-id pub-id-type="pmid">18632860</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref082">
<label>82</label>
<mixed-citation publication-type="journal"><name><surname>Latos</surname><given-names>PA</given-names></name>, <name><surname>Pauler</surname><given-names>FM</given-names></name>, <name><surname>Koerner</surname><given-names>MV</given-names></name>, <name><surname>Senergin</surname><given-names>HB</given-names></name>, <name><surname>Hudson</surname><given-names>QJ</given-names></name>, <name><surname>Stocsits</surname><given-names>RR</given-names></name>, <etal>et al</etal>
<article-title>Airn transcriptional overlap, but not its lncRNA products, induces imprinted Igf2r silencing</article-title>. <source/>Science. <year>2012</year>;<volume>338</volume>(<issue>6113</issue>):<fpage>1469</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1126/science.1228110</pub-id> .<pub-id pub-id-type="pmid">23239737</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref083">
<label>83</label>
<mixed-citation publication-type="journal"><name><surname>Calin</surname><given-names>GA</given-names></name>, <name><surname>Liu</surname><given-names>CG</given-names></name>, <name><surname>Ferracin</surname><given-names>M</given-names></name>, <name><surname>Hyslop</surname><given-names>T</given-names></name>, <name><surname>Spizzo</surname><given-names>R</given-names></name>, <name><surname>Sevignani</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas</article-title>. <source/>Cancer cell. <year>2007</year>;<volume>12</volume>(<issue>3</issue>):<fpage>215</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2007.07.027</pub-id> .<pub-id pub-id-type="pmid">17785203</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref084">
<label>84</label>
<mixed-citation publication-type="journal"><name><surname>Schmitt</surname><given-names>AM</given-names></name>, <name><surname>Chang</surname><given-names>HY</given-names></name>. <article-title>Long Noncoding RNAs in Cancer Pathways</article-title>. <source/>Cancer cell. <year>2016</year>;<volume>29</volume>(<issue>4</issue>):<fpage>452</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2016.03.010</pub-id>
<pub-id pub-id-type="pmid">27070700</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref085">
<label>85</label>
<mixed-citation publication-type="journal"><name><surname>Xiang</surname><given-names>JF</given-names></name>, <name><surname>Yin</surname><given-names>QF</given-names></name>, <name><surname>Chen</surname><given-names>T</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>XO</given-names></name>, <name><surname>Wu</surname><given-names>Z</given-names></name>, <etal>et al</etal>
<article-title>Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus</article-title>. <source/>Cell research. <year>2014</year>;<volume>24</volume>(<issue>5</issue>):<fpage>513</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2014.35</pub-id>
<pub-id pub-id-type="pmid">24662484</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref086">
<label>86</label>
<mixed-citation publication-type="journal"><name><surname>Ling</surname><given-names>H</given-names></name>, <name><surname>Spizzo</surname><given-names>R</given-names></name>, <name><surname>Atlasi</surname><given-names>Y</given-names></name>, <name><surname>Nicoloso</surname><given-names>M</given-names></name>, <name><surname>Shimizu</surname><given-names>M</given-names></name>, <name><surname>Redis</surname><given-names>RS</given-names></name>, <etal>et al</etal>
<article-title>CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer</article-title>. <source/>Genome research. <year>2013</year>;<volume>23</volume>(<issue>9</issue>):<fpage>1446</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1101/gr.152942.112</pub-id>
<pub-id pub-id-type="pmid">23796952</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref087">
<label>87</label>
<mixed-citation publication-type="journal"><name><surname>Gilroy</surname><given-names>KL</given-names></name>, <name><surname>Terry</surname><given-names>A</given-names></name>, <name><surname>Naseer</surname><given-names>A</given-names></name>, <name><surname>de Ridder</surname><given-names>J</given-names></name>, <name><surname>Allahyar</surname><given-names>A</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Gamma-Retrovirus Integration Marks Cell Type-Specific Cancer Genes: A Novel Profiling Tool in Cancer Genomics.</article-title>
<source/>PloS one. <year>2016</year>;<volume>11</volume>(<issue>4</issue>):<fpage>e0154070</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0154070</pub-id>
<pub-id pub-id-type="pmid">27097319</pub-id></mixed-citation>
</ref>
<ref id="pone.0213770.ref088">
<label>88</label>
<mixed-citation publication-type="journal"><name><surname>Sasani</surname><given-names>F</given-names></name>, <name><surname>Baghban</surname><given-names>F</given-names></name>, <name><surname>Nikbakht Brujeni</surname><given-names>GH</given-names></name>, <name><surname>Kazemi</surname><given-names>M</given-names></name>. <article-title>TP53 intronic mutations in bovine enzootic hematuria-associated urinary bladder tumors</article-title>. <source/>Vet Pathol. <year>2013</year>;<volume>50</volume>(<issue>3</issue>):<fpage>543</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1177/0300985812469632</pub-id> .<pub-id pub-id-type="pmid">23242803</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>